

D E S C R I P T I O N

TITLE OF THE INVENTION

5 COMPOSITIONS FOR CURING AFFECTED
ABNORMAL TISSUES, METHOD FOR THE PREPARATION THEREOF,
AND USAGE THEREOF

TECHNICAL BACKGROUND

10 The present invention relates to a composition
for curing affected abnormal tissues, a method for the
preparation thereof, and usage thereof and, more parti-
cularly, to a composition for curing affected abnormal
15 tissues caused, for example, by piles or hemorrhoids and
the like, which is stable during storage for a long period
of time, a method for the preparation of the composition
therefor, and usage for curing such affected abnormal
tissues by using the composition therefor.

20 BACKGROUND ART

Injection therapy of internal piles or hemor-
rhoids has a history of more than 100 years. The early
injections used for the such therapy were composed of a
ferrous sulfate solution, phenol in olive oil, and the
25 like. Thereafter, there were used alcohol, quinine
hydrochloride, mercuric chloride, urethan, ergot and the
like. In the past thirty years, a phenol solution in
vegetable oil and an alum solution have been used most
frequently for curing the internal piles or hemorrhoids.

30 These compositions, however, cannot be said to
satisfactorily solve all or most of such problems for
curing internal piles or hemorrhoids for reasons as will
be described hereinafter. It is noted that the injection
therapy for sclerosing the internal piles or hemorrhoids
35 requires for the injectable preparations to reduce inflam-
mation, to stop bleeding, to inhibit the growth of

REPLACED SHEETS		SG
☒	Description : paged 1 to paged 42	
☒	Claim(s) : paged 43 to paged 47	
☐	Drawing(s) : paged to paged	
☒	Abstract : paged 48 to paged 49	
DATE OF RECEIPT		

This Sheet Has Been Replaced



bacteria, to bring about well-formed thrombosis and to complete fibrosis of hemorrhoidal blood vessels without leaving any hard nodules or causing necrosis. The injectable preparations so far developed for curing the internal piles or hemorrhoids by sclerosing the affected abnormal tissues of the digestive system, however, do not satisfy any or a majority of the requirements as described immediately hereinabove. It is also noted as difficult to determine the appropriate concentration and quantity of the injectable preparations used at clinical needs, as well as a procedure to sclerose the internal piles or hemorrhoids without causing necrosis. It is further required that the methods of injection therapy and administration be improved so as to expand the injected area because the composition be deposited only in the submucosa when injected.

As a composition for curing internal piles or hemorrhoids, there is proposed an injectable agent that comprises tannin, alum, sodium citrate, dextran, glycerin and trichlorobutyl alcohol (Journal of Traditional Chinese Medicine: vol. 1, No. 2, pp. 116-120 (1981)). Alum has a chemical nomenclature as aluminum potassium sulfate and it is a colorless and transparent substance of an octahedral crystal. It has locally astringent, hemostatic and antiseptic properties. Alum is not absorbed through the gastroenteric mucosa when administered internally and exerts merely a local action against the mucosa. On the other hand, tannic acid is usually obtained from nutgall or gall and may be a yellow-white or pale brown, amorphous and powdery substance or a small-leaf-shaped or spongy bulky substance. Tannic acid can cause a protein to coagulate in an acidic or neutral solution and has astringent, antiseptic and anti-bacterial properties.

It is further noted that aluminum potassium sulfate is not allowed to be practically used in combination with tannic acid or tannin agents (Pharmacopedia



Japonica, The 12th Revision (1991); pp. D-1019-1021). In addition, it is also known that tannic acid forms a less soluble salt with basic organic chemical substances and a non-soluble or sparingly soluble compound with an iron agent or the like, thereby losing its effects.

The injectable preparations as described immediately hereinabove contains trichlorobutyl alcohol so that there is the possibility that it presents the problems as will be described hereinafter. It is known that trichlorobutyl alcohol is a compound in which carbon atoms and chlorine atoms are combined with each other and it can oxidize tannic acid due to the formation of a radical upon the absorption of light, thereby causing tannic acid to turn into precipitated materials having a brown or black color. Further, trichlorobutyl alcohol has the property that the linkage between the carbon and chlorine atoms is broken upon application of high energy such as heat or light, turning into unstable substances. It is thus said to be inappropriate to use trichlorobutyl alcohol as a component of a medicine due to its such property because there is the highly probable risk that it causes precipitates in the injectable preparations during storage. In addition, the use of such a compound is less convenient in handling and storing because the greatest possible care is required for storing the injectable preparations containing it.

Further, Japanese Patent Unexamined Publication Kokai No. 4-225,920 discloses an agent for hardening or sclerosing the affected abnormal tissues of the digestive system such as, for example, esophagophlebangioma, piles or hemorrhoids, rectal prolapse, prolapse of the rectal mucosa and the affected uplift tissues of the large intestine and the rectum. The sclerosing agent consists of a composition comprising tannic acid, aluminum potassium sulfate and a stabilizing agent including an extract of a medicinal plant, containing a phenol, a flavone or a

This Sheet Has Been Replaced



flavonoid, a catechin or a polycarboxylic acid. As this composition contains the extract of the medicinal plant as the stabilizing agent, however, it suffers from the disadvantages in terms of formulating preparations that it is extremely difficult to provide injectable preparations with a constant formulation and stable quality as well as that there is still the possibility that the stabilizing agent may be contaminated with minute amounts of unidentified substances even if it would be extracted and purified elaborately through plural steps. It has further been found that such a composition comprising tannic acid and aluminum potassium sulfate may cause coloring or, in some cases, precipitating, even if it contains the extract of the plant as a stabilizing agent, when stored for a long period of time in a liquid state. This also may cause the problem when it is applied as an injectable agent.

In addition, PCT International Publication No. W094/06443 (International Publication Date: March 31, 1994) discloses a composition for curing affected abnormal tissues of the digestive system as injectable preparations, which comprises a composition containing a water-soluble aluminum compound in a concentration ranging from 0.01 mole to 0.5 mole, tannic acid at a rate of 0.5% to 25.0% with respect to the amount of the water-soluble aluminum compound, sodium hydrogen sulfite, and a polyvalent alcohol or a saccharide; in which a pH of said composition is adjusted so as to become in the range of from pH1.5 to pH3.5. The components of the compositions disclosed in this publication are the same as those of the ones to which the present invention is directed. This publication, however, discloses a method for the preparation of the composition for curing the affected abnormal tissues of the digestive system as well as the compositions consisting of the same components as those of the present invention. The published method comprises formu-



lating all the components of the composition in a simultaneous way or in a random way. More specifically, the method for the preparation of the hardening or sclerosing agent disclosed in this publication comprises placing all the components in a test tube, pouring a predetermined amount of distilled water for injection use with stirring in the test tube, and dissolving them to give an aqueous solution. The resulting aqueous solution is then filled in a container such as a glass bottle, followed by removal of oxygen dissolved in the solution and replenishment of air with nitrogen gases. Thereafter, the solution is sterilized with high-pressure steam and then stored in a cold and dark place. It has been found, however, that the general method for the formulation of the composition as disclosed in this publication suffers from the extreme difficulty in preparing a stable composition with the constant formulation and that it presents the problem in the actual preparation of the compositions as an injectable agent.

Aluminum potassium sulfate, which may also be called alum and is used as one component for the composition according to the present invention, has been applied as an a hemostatic agent. As described hereinabove, however, a combination of aluminum potassium sulfate with a tannic agent is prohibited to be used as medicine as set forth in Pharmacopedia Japonica. Nevertheless, various attempts have been made to use aluminum potassium sulfate in combination with the tannic agent as medicine; however, aluminum potassium sulfate is very unstable when it is mixed with the tannic agent as it is because it may be caused to become colored or to precipitate. Hence, the use of such an unstable composition as injectable preparations is inappropriate even in terms of safety.

Further, aluminum potassium sulfate usually contains a small amount of iron because it is prepared



from bauxite as a raw material. Pharmacopedia Japonica regulates the acceptable contents of iron derivatives to be 20 ppm or less when aluminum potassium sulfate is employed as a raw material for medicine.

5 In addition, aluminum potassium sulfate may be caused to be decomposed into aluminum ions such as Al^{3+} , $\text{Al}(\text{OH})^{2+}$, $\text{Al}(\text{OH})^+$ and the like upon dissociation in a solution and react with hydroxyl ion, OH^- , to form aluminum hydroxide, $\text{Al}(\text{OH})_3$, which are caused to precipitate in
10 a solution. If such precipitates are formed in the solution, it is inappropriate to employ it as a composition for injectable preparations and it cannot be applied for treatment.

 On the other hand, tannic acid is oxidized to
15 form an oxide compound such as a quinone compound upon exposure to oxygen existing in air or dissolved in a solution to be used, thereby causing precipitates when the solution is used for injectable preparations. If such insoluble products are caused to precipitate in the
20 injectable preparations, the resulting injection becomes as a matter of course inappropriate as medicine and cannot be administered.

 Further, tannic acid is caused to be oxidized forming precipitates, particularly when iron ions are
25 present in the solution. Hence, if tannic acid exists with aluminum potassium sulfate in the solution, the iron ions present in the aluminum potassium sulfate contained in the solution are reacted directly with tannic acid, leading to the formation of precipitates, and the oxidation of
30 tannic acid is accelerated.

 In addition, tannic acid is allowed to react directly with aluminum ions, causing to form precipitates, if the aluminum ions are present in the solution, and it is likely to undergo oxidation.

35 Accordingly, a composition containing aluminum potassium sulfate and tannic acid cannot be prepared in



a constant and stable manner without causing any precipitates simply by formulating all the components in a simultaneous or random way.

5 As the result of a detailed review on the order and conditions of formulating the components in preparing the preparations for injection, it has been found by the present inventor that the injectable preparations for curing the affected abnormal tissues having a constant and stable composition can be prepared by arranging the order
10 of formulation of its components and the concentrations thereof. Thus, the present invention has been completed from this finding.

DISCLOSURE OF INVENTION

15 Therefore, the present invention can solve the problems involved in conventional compositions for curing the affected abnormal tissues and the present invention has the objects to provide an composition for curing the affected abnormal tissues with improved effects, to
20 provide a method for the production of the injectable preparations having a constant and stable formulation, and to provide the use of the composition for application in order to cure piles or hemorrhoids, affected uplift tissues of the digestive tracts, hepatic tumor, and the
25 like.

The composition for curing the affected abnormal tissues in accordance with the present invention may comprise substantially a water-soluble aluminum compound, tannic acid, a chelating agent, and sodium hydrogen
30 sulfite. The pH range of the composition is adjusted to be from pH1.0 to pH3.5.

Alternatively, the composition for curing the affected abnormal tissues according to the present invention may further comprise the polyvalent alcohol
35 and/or saccharide in addition to the formulation consisting of the water-soluble aluminum compound, the chelating



agent, tannic acid and sodium hydrogen sulfite, the composition being adjusted, as needed, to a pH ranging from pH1.0 to pH3.5.

As the water-soluble aluminum compound to be employed for the composition for curing the affected abnormal tissues in accordance with the present invention, there may be mentioned, for example, aluminum chloride, aluminum sulfate, aluminum carbonate, aluminum acetate, aluminum nitrate, aluminum lactate, aluminum tartrate, aluminum salicylate, aluminum sodium sulfate, aluminum potassium sulfate, aluminum cesium sulfate, ammonium aluminum sulfate and the like. The water-soluble aluminum compounds may be applied singly or in combination of two or more.

The water-soluble aluminum compound may be formulated in concentrations ranging usually from 0.01 to 0.5 mole, preferably from 0.03 to 0.3 mole. It is preferred that the water-soluble aluminum compound is contained so as to amount to from approximately 1% to 10%, preferably from approximately 2% to 5%, as the effective concentrations in the injectable preparations.

As tannic acid to be employed for the curing injectable solution according to the present invention, there may be employed one derived from a variety of plants. The most preferred one is tannic acid derived from gallnut. Tannic acid may be contained at a rate ranging usually from 0.01% to 2.0%, preferably from 0.05% to 1.5%, as the effective concentrations in the injectable preparations. The tannic acid may be added in a concentration beyond the above range by adjusting the amounts of the other components, particularly sodium hydrogen sulfite; however, in this case, care should be paid in preparing and storing the compositions because the resulting compositions are likely to cause coloring or precipitating or depositing during storage for a long period of time. In this sense, such compositions are inconvenient in handling.



As described hereinabove, aluminum potassium sulfate may be decomposed to form aluminum ions such as Al^{3+} , $\text{Al}(\text{OH})^{2+}$, $\text{Al}(\text{OH})^+$ and the like upon dissociation in the solution and react with hydroxyl ion, OH^- , to form aluminum hydroxide, $\text{Al}(\text{OH})_3$. If such aluminum ions are present in the solution, tannic acid is reacted directly with them, whereby the solution is likely to cause precipitating.

As the chelating agent to be employed for the present invention, there may be mentioned any compound having the action of trapping minute amounts of metal ions present in the solution. The chelating agent may include, for example, citric acid or a salt thereof such as sodium citrate. The amount of the chelating agent may be in the range of from approximately 10% to 80%, preferably from approximately 20% to 50%, with respect to the amount of the water-soluble aluminum compound, although the amount of the chelating agent may be varied with the kind or the amount of the water-soluble aluminum compound, or the like.

In preparing the compositions for curing the affected abnormal tissues in accordance with the present invention, the chelating agent such as sodium citrate is added to a solution containing the water-soluble aluminum compound before formulating tannic acid with the water-soluble aluminum compound, in order to avoid the direct reaction of the tannic acid with the water-soluble aluminum compound and to cause no precipitating. Once the chelating agent is added to the solution containing the water-soluble aluminum compound, the chelating agent is caused to react with the aluminum ions present in the solution, resulting in the formation of complex aluminum ions and removing the metal ions from the solution to which tannic acid is to be added, the metal ions being reactable with the tannic acid and as a result being likely to cause forming precipitates. To the solution



treated in the manner as described hereinabove is added tannic acid to thereby yield a solution in which the tannic acid is not reacted directly with the metal ions, such as aluminum ions, derived from the water-soluble aluminum compound and in which no precipitates are formed. Theoretically, for example, if 0.65 molecule of the aluminum ion is present with respect to one molecule of sodium citrate ion and the former is to be linked to the latter, no free aluminum ion is present in the solution. Practically, however, as the sodium citrate ion exists in a neutral state or in the form of a citric acid dihydrogen ion in the range of such a strong acid as the composition according to the present invention, such amounts are insufficient to trap the aluminum ions in the 1.65-fold concentrations as complex ions. Hence, in this case, it is preferred to select a solution having the composition so as to allow free aluminum ions to exist in a range that does not exceed a solubility product constant of aluminum tannate.

Further, tannic acid is unstable against light or air in a solid state and it is lesser stable in the solution from the point of view of a diffusion velocity between the reactive substances. For the purpose to prevent oxidation of tannic acid, there may be used an antioxidant such as, for example, sodium hydrogen sulfite. The rate of sodium hydrogen sulfite to be used as the antioxidant in accordance with the present invention may be usually from approximately 50% to 200%, preferably from approximately 70% to 150%, with respect to the amount of the tannic acid. If the sodium hydrogen sulfite would be contained in a concentration beyond the above range, the resulting injectable preparations cannot accomplish the desired effects sought to be achieved by the present invention.

In order to make the composition according to the present invention more stable, there may be added as



needed the polyvalent alcohol and/or saccharide, which are or is conventionally employed for curable compositions. As the polyvalent alcohol and/or the saccharide to be employed for the present invention, there may be mentioned
5 glycerin, glucose, fructose, xylitol, mannose, mannitol, galactose, dextran and the like. Particularly, dextran has the action of raising the viscosity of the resulting injectable preparations. The polyvalent alcohol and/or saccharide may be employed singly or in combination of two
10 or more. Further, the amount of the polyvalent alcohol and/or saccharide is not limited to a particular one as long as the polyvalent alcohol and/or saccharide may be contained at such a rate so as to raise the osmosis of the resulting injectable preparations by approximately three
15 times to fifteen times, preferably from approximately four times to eight times, that of physiological saline. In addition, the polyvalent alcohol and/or saccharide are or is preferably contained in the range of from approximately 3% to 20%, preferably from approximately 5% to 15%, as the
20 effective concentration in the injectable preparations.

Further, the compositions according to the present invention may contain another component which hitherto has been conventionally employed as an ingredient for compositions, such as an agent for increasing viscosity of a solution, e.g. dextran or the like, or an anti-septic agent, e.g. phenol, benzyl alcohol, benzalkonium
25 chloride, p-aminobenzoic acid ester or the like. These components may optionally be employed within the range that does not substantially affect the effects of the compositions adversely.
30

In accordance with the present invention, it is of significance in terms of storage of the resulting preparations that the liquid property of the injectable preparations containing the composition is adjusted to be
35 from pH1.0 to pH3.5, preferably from pH2.0 to pH3.0.

When the compositions according to the present



invention can be prepared by means of the method according to the present invention, the liquid properties of the compositions may be usually set within the above-defined range without special adjustment and, in this case, it is not particularly required to adjust the liquid properties of the resulting injectable preparations after or before the preparation of the compositions. It is also possible to adjust the liquid properties of the compositions, as needed, to the optimal level with a pharmacologically non-toxic acid or alkali, which are conventionally used for the formulation of the injectable preparations. Such agents may include, for example, a mineral acid such as hydrochloric acid or sulfuric acid, an organic acid such as citric acid, sodium hydrogen carbonate, sodium hydroxide or the like. The preparations having the liquid properties within the range as defined hereinabove can be stored in an extremely stable manner for a long period of time without causing any coloring or depositing or precipitating.

In order to prepare the compositions for curing the affected abnormal tissues according to the present invention from the components as described hereinabove, it is necessary to formulate each of the components in accordance with the order and conditions of formulation, as will be described hereinafter, with the properties of each component taken into consideration.

Specifically, the compositions according to the present invention can be prepared by formulating the sodium hydrogen sulfite, the water-soluble aluminum compound and the chelating agent in an optional order into a formulation and adding tannic acid to the resulting formulation.

In addition, the polyvalent alcohol and/or the saccharide may be added to the formulation or a mixture prepared by adding tannic acid to the formulation.

Alternatively, the compositions for curing the



affected abnormal tissues according to the present invention may be prepared by separately forming a formulation by admixing the water-soluble aluminum compound with the chelating agent and a formulation by admixing tannic acid with the sodium hydrogen sulfite and then combining the two formulations together into the compositions.

In this case, too, the polyvalent alcohol and/or the saccharide may be added to either one or both of the formulations prepared in the alternative manner as have been described hereinabove or the mixture obtained by combining the two formulations.

In summary, the methods for the preparation of the compositions for curing the affected abnormal tissues according to the present invention may comprise, as a method, adding tannic acid to the formulation prepared by admixing sodium hydrogen sulfite with all the components other than tannic acid and sodium hydrogen sulfite in an optional way or, as an alternative method, separately preparing the formulation by admixing the water-soluble aluminum compound with the chelating agent and the another formulation by admixing the tannic acid with the sodium hydrogen sulfite and then combining the formulation together with the another formulation into the mixture and, as needed, adding the polyvalent alcohol and/or saccharide to the formulation or formulations or to the mixture at any stage of preparation. By formulating each of the components in the manner as described hereinabove, the oxidation of tannic acid can be prevented as well as the direct reaction of tannic acid with the metal ions such as the aluminum ions derived from the water-soluble aluminum compound can also be prevented, thereby enabling the formation of the stable compositions for curing the affected abnormal tissues according to the present invention in a constant manner.

In the method for the preparation of the compositions for curing the affected abnormal tissues



according to the present invention, the pH range of the compositions can be made, as needed, at any stage of formulation or admixture of the components so as for the resulting injectable preparations to demonstrate the liquid properties within the above-defined level, i.e. from pH1.0 to pH3.5. More specifically, when the compositions are prepared by adding tannic acid to the formulation prepared by admixing all the components other than the tannic acid, the liquid properties of the injectable preparations can be adjusted at any or every stage of formulation or admixture by admixing the water-soluble aluminum compound and the chelating agent with sodium hydrogen sulfite and admixing tannic acid to the resulting formulation and adding the polyvalent alcohol and/or saccharide to the resulting mixture as needed. Alternatively, when the compositions are prepared by admixing the formulation consisting of the water-soluble aluminum compound and the chelating agent with the formulation consisting of the tannic acid and the sodium hydrogen sulfite, the liquid properties of the injectable preparations can also be adjusted at any or every stage of formulation or admixture to the above-defined level by admixing the resulting formulations together with each other to yield the mixture and adding the polyvalent alcohol and/or saccharide to the resulting mixture as needed.

In the methods for the preparation of the compositions for curing the affected abnormal tissues according to the present invention, it is preferred that any or every component of the composition is formulated with each other under atmosphere of an inert gas. As the inert gases to be used for this purpose, there may preferably be mentioned, for example, nitrogen gases.

Further, it is preferred that the compositions according to the present invention are prepared by formulating each of the components under conditions under



which oxygen does not exist in an atmosphere or in water to be used in no substantial amount or in an amount restricted within the level that does not adversely affect the resulting compositions. Such level may be, for example, 1/1,000 or less with respect to the level in a stationary state.

The compositions thus prepared in the manner as described hereinabove are then filtered and sterilized by means of conventional methods and filled in a container such as colorless hard glass ampoules or glass bottles. They are then sterilized by high-pressure steam, as needed, and stored in a cold place.

In accordance with the method for the preparation of the compositions for curing the affected abnormal tissues, it is preferred that each or every step of the method be carried out in the presence of inert gases such as nitrogen gases. The oxygen dissolved in the injectable preparations are usually removed by conventional methods and the air present in the injectable preparations is replenished with nitrogen gases.

The compositions according to the present invention can be lyophilized by conventional methods. They also can be applied by dissolving the components in distilled water in site. In this case, a solution prepared by dissolving the polyvalent alcohol and/or saccharide may also be used as a solution for use in dissolving the compositions in site.

The compositions for curing the affected abnormal tissues according to the present invention have the peculiar properties of killing the affected abnormal tissues of the digestive organs, particularly the large intestine and rectum, upon contact with the locations of the tissues affected with the piles or hemorrhoids, such as internal piles or hemorrhoids, archoptoma or the like, the uplift affected tissues, the tissues affected with hepatic tumor and the like.



The compositions according to the present invention can demonstrate the strong action of killing the cells of the affected abnormal tissues while holding the states or shapes of the cells. In other words, it is anticipated that the compositions can kill the cells of the affected abnormal tissues upon contact by application and then cause the killed cells to fall off from the normal tissues. By allowing the killed cells to fall off from the normal tissues, the compositions according to the present invention can sclerose the affected abnormal tissues and cure them in mild conditions.

BEST MODE FOR CARRYING OUT THE INVENTION

The compositions for curing the affected abnormal tissues according to the present invention will be described in more detail by way of examples.

Example No. 1:

The composition for curing the affected abnormal tissues according to this example contained the following components:

	Aluminum potassium sulfate	400 mg
10	Sodium citrate	150 mg
	Sodium hydrogen sulfite	15 mg
	Tannic acid	15 mg
	Dextran 40	70 mg
	Glycerin	1,000 mg
15	Injectable distilled water	To make 10 ml

The injectable distilled water prepared so as to comply with Pharmacopedia Japonica was treated to remove dissolved oxygen by heating it at 100 °C for five minutes. After the completion of heating, nitrogen gases were introduced into the treated water and allowed to cool to room temperature.

Separately, the total amount of dextran 40 was fully dissolved in an appropriate solvent in advance because it is less soluble to the solution for use.



The total amount of sodium hydrogen sulfite was dissolved into an appropriate amount of the injectable distilled water, and the resulting solution was added with the dextran 40 solution and then with sodium citrate, followed by the addition thereto of the total amounts of aluminum potassium sulfate and glycerin. To the resulting solution was added the total amount of tannic acid. The formulation of each of the components was carried out while nitrogen gases had been kept introduced thereinto. The resulting solution was stirred for about 30 minutes and filtered through a filter. Into the filtrate were introduced nitrogen gases to yield the objective composition. The composition had a pH of 2.7.

The resulting solution was then filled in glass vials or ampoules. Before and after filling, the air in the solution was replenished with nitrogen gases and the vials or ampoules were sealed, followed by storage in a cold dark place.

Example No. 2:

The composition having the same components as the one prepared in Example No. 1 was prepared in substantially the same manner as in Example No. 1 with the exception that the dextran 40 solution, sodium citrate, aluminum potassium sulfate and glycerin were added in the order of sodium citrate, aluminum potassium sulfate, glycerin and the dextran 40 solution. The resulting composition had a pH of 2.6.

Example No. 3:

The composition having the same components as the one prepared in Example No. 1 was prepared in substantially the same manner as in Example No. 1 with the exception that the dextran 40 solution, sodium citrate, aluminum potassium sulfate and glycerin were added in the order of aluminum potassium sulfate, glycerin, the dextran 40 solution and sodium citrate. The resulting composition had a pH of 2.7.



Example No. 4:

The composition having the same components as the one prepared in Example No. 1 was prepared in substantially the same manner as in Example No. 1 with the exception that the dextran 40 solution, sodium citrate, aluminum potassium sulfate and glycerin were added in the order of glycerin, the dextran 40 solution, sodium citrate and aluminum potassium sulfate. The resulting composition had a pH of 2.7.

10 Example No. 5:

The composition for curing the affected abnormal tissues according to this example contained the following components:

	Aluminum chloride	400 mg
15	Tannic acid	15 mg
	Sodium citrate	150 mg
	Dextran 40	70 mg
	Sodium hydrogen sulfite	15 mg
	Mannitol	1,500 mg
20	Injectable distilled water	To make 10 ml

The injectable distilled water was treated to remove dissolved oxygen by heating at 100 °C for five minutes. After the completion of heating, nitrogen gases were introduced into the treated water and allowed to cool to room temperature.

The total amount of sodium hydrogen sulfite was dissolved into an appropriate amount of the injectable distilled water thermally treated, and the resulting solution was added with the dextran 40 solution prepared separately and then with sodium citrate, followed the addition thereto of the total amounts of aluminum chloride and mannitol. To the resulting solution was then added the total amount of tannic acid yielding a solution. The formulation of each of the components was carried out while nitrogen gases had been kept introduced thereinto. The resulting solution was stirred for about 30 minutes,



added with hydrochloric acid to adjust its pH to pH3.0 and filtered through a filter. Into the filtrate were introduced nitrogen gases to yield the objective composition.

5 The resulting solution was then filled in glass vials or ampoules. Before and after filling, the air in the solution was replenished with nitrogen gases and the vials or ampoules were sealed, followed by storage in a cold dark place.

Example No. 6:

10 The composition of this example contained the components as follows:

	Aluminum sulfate	400 mg
	Tannic acid	15 mg
	Sodium citrate	150 mg
15	Dextran 40	70 mg
	Sodium hydrogen sulfite	15 mg
	Fructose	2,000 mg
	Injectable distilled water	To make 10 ml

20 The injectable preparations were prepared by formulating each of the components in substantially the manner as in Example No. 5 with the exception that aluminum chloride was replaced with aluminum sulfate and mannitol was replaced with fructose. The resulting composition had a pH of 2.7.

25 Example No. 7:

The composition of this example contained the components as follows:

	Aluminum carbonate	200 mg
	Tannic acid	15 mg
30	Sodium citrate	150 mg
	Dextran 40	70 mg
	Sodium hydrogen sulfite	15 mg
	Xylitol	2,000 mg
	Injectable distilled water	To make 10 ml

35 The injectable preparations were prepared in substantially the same manner as in Example No. 5 with the



exception that aluminum chloride was replaced with aluminum carbonate and mannitol was replaced with xylitol. The resulting composition was treated with sulfuric acid to give a pH of 2.7.

5 Example No. 8:

The composition of this example contained the components as follows:

	Aluminum acetate	200 mg
	Tannic acid	15 mg
10	Sodium citrate	150 mg
	Dextran 40	70 mg
	Sodium hydrogen sulfite	15 mg
	Glucose	3,000 mg
	Injectable distilled water	To make 10 ml

15 The injectable preparations were prepared in substantially the same manner as in Example No. 5 with the exception that aluminum chloride was replaced with aluminum acetate and mannitol was replaced with glucose. The resulting composition was treated with sulfuric acid
20 to give a pH of 2.7.

Example No. 9:

The composition for curing the affected abnormal tissues according to this example contained the components as follows:

25	Aluminum potassium sulfate	400 mg
	Tannic acid	15 mg
	Sodium citrate	150 mg
	Dextran 40	70 mg
	Sodium hydrogen sulfite	10 mg
30	Glycerin	1,000 mg
	Injectable distilled water	To make 10 ml

The injectable preparations were prepared by formulating the above components in substantially the same manner as in Example No. 1. The resulting composition was
35 adjusted with sulfuric acid to a pH of 2.7.

Example No. 10:

This Sheet Has Been Replaced



The composition for curing the affected abnormal tissues according to this example contained the components as follows:

	Aluminum potassium sulfate	400 mg
5	Tannic acid	30 mg
	Sodium citrate	150 mg
	Dextran 40	70 mg
	Sodium hydrogen sulfite	30 mg
	Glycerin	1,000 mg
10	Injectable distilled water	To make 10 ml

The injectable preparations were prepared by formulating the above components in substantially the same manner as in Example No. 1. The resulting composition was adjusted with sulfuric acid to a pH of 2.8.

15 Example No. 11:

The composition for curing the affected abnormal tissues according to this example contained the components as follows:

	Aluminum potassium sulfate	400 mg
20	Tannic acid	50 mg
	Sodium citrate	150 mg
	Dextran 40	70 mg
	Sodium hydrogen sulfite	70 mg
	Glycerin	1,000 mg
25	Injectable distilled water	To make 10 ml

The injectable preparations were prepared by formulating the above components in substantially the same manner as in Example No. 1. The resulting composition was adjusted with sulfuric acid to a pH of 2.7.

30 Example No. 12:

The composition for curing the affected abnormal tissues according to this example contained the components as follows:

	Aluminum potassium sulfate	400 mg
35	Tannic acid	70 mg
	Sodium citrate	150 mg



Dextran 40	70 mg
Sodium hydrogen sulfite	70 mg
Glycerin	1,000 mg
Injectable distilled water	To make 10 ml

5 The injectable preparations were prepared by formulating the above components in substantially the same manner as in Example No. 1. The resulting composition had a pH of 3.2.

Example No. 13:

10 The composition for curing the affected abnormal tissues according to this example contained the components as follows:

Aluminum potassium sulfate	400 mg
Tannic acid	90 mg
15 Sodium citrate	150 mg
Dextran 40	70 mg
Sodium hydrogen sulfite	100 mg
Glycerin	1,000 mg
Injectable distilled water	To make 10 ml

20 The injectable preparations were prepared by formulating the above components in substantially the same manner as in Example No. 1. The resulting composition was adjusted with sulfuric acid to a pH of 2.7.

Example No. 14:

25 The composition for curing the affected abnormal tissues according to this example contained the components as follows:

Aluminum potassium sulfate	400 mg
Tannic acid	100 mg
30 Sodium citrate	150 mg
Dextran 40	70 mg
Sodium hydrogen sulfite	100 mg
Glycerin	1,000 mg
Injectable distilled water	To make 10 ml

35 The injectable preparations were prepared by formulating the above components in substantially the same



manner as in Example No. 1. The resulting composition was adjusted with sulfuric acid to a pH of 2.7.

Example No. 15:

5 The composition for curing the affected abnormal tissues according to this example contained the components as follows:

Aluminum potassium sulfate	400 mg
Tannic acid	120 mg
Sodium citrate	150 mg
10 Sodium hydrogen sulfite	140 mg
Glycerin	1,200 mg
Injectable distilled water	To make 10 ml

The injectable preparations were prepared by formulating the above components in substantially the same manner as in Example No. 1. The resulting composition was adjusted with sulfuric acid to a pH of 2.7.

Example No. 16:

20 The composition for curing the affected abnormal tissues according to this example contained the components as follows:

Aluminum potassium sulfate	400 mg
Tannic acid	15 mg
Sodium citrate	300 mg
Sodium hydrogen sulfite	20 mg
25 Mannitol	3,000 mg
Injectable distilled water	To make 10 ml

The injectable preparations were prepared in substantially the same manner as in Example No. 1 with the exception that dextran was not used and glycerin was replaced with mannitol. The resulting composition was adjusted with sulfuric acid to a pH of 2.7.

Example No. 17:

35 The composition for curing the affected abnormal tissues according to this example contained the components as follows:

Aluminum potassium sulfate	400 mg
----------------------------	--------



	Sodium citrate	50 mg
	Sodium hydrogen sulfite	15 mg
	Tannic acid	15 mg
	Glycerin	1,100 mg
5	Injectable distilled water	To make 10 ml

The injectable distilled water prepared so as to comply with Pharmacopedia Japonica was treated to remove dissolved oxygen by heating at 100 °C for five minutes. After the completion of heating, nitrogen gases were introduced into the treated water and allowed to cool to room temperature.

The total amount of sodium hydrogen sulfite was dissolved into an appropriate amount of the injectable distilled water, and the resulting solution was added with sodium citrate, followed by the addition thereto of the total amounts of aluminum potassium sulfate and glycerin. To the resulting solution was added the total amount of tannic acid. The formulation of each of the components was carried out while nitrogen gases had been kept introduced thereinto. The resulting solution was stirred for about 30 minutes, adjusted with sulfuric acid to demonstrate a pH of 3.1, and filtered through a filter. Into the filtrate were introduced nitrogen gases to yield the objective composition.

The resulting solution was then filled in glass vials or ampoules. Before and after filling, the air in the solution was replenished with nitrogen gases and the vials or ampoules were sealed, followed by storage in a cold dark place.

Example No. 18:

The composition for curing the affected abnormal tissues according to this example contained the components as follows:

	Aluminum potassium sulfate	400 mg
35	Sodium citrate	100 mg
	Sodium hydrogen sulfite	15 mg

This Sheet Has Been Replaced



Tannic acid	15 mg
Dextran 40	100 mg
Injectable distilled water	To make 10 ml

5 The injectable distilled water prepared so as to comply with Pharmacopedia Japonica was treated to remove dissolved oxygen by heating at 100 °C for five minutes. After the completion of heating, nitrogen gases were introduced into the treated water and allowed to cool to room temperature.

10 The total amount of sodium hydrogen sulfite was dissolved into an appropriate amount of the injectable distilled water, and the resulting solution was added with the total amounts of the dextran 40 solution separately prepared and sodium citrate, followed by the addition
15 thereto of the total amount of aluminum potassium sulfate. To the resulting solution was added the total amount of tannic acid. The formulation of each of the components was carried out while nitrogen gases had been kept introduced thereinto. The resulting solution was stirred for about
20 30 minutes, adjusted with sulfuric acid to give a pH of 2.8, and filtered through a filter. Into the filtrate were introduced nitrogen gases to yield the objective composition.

25 The resulting solution was then filled in glass vials or ampoules. Before and after filling, the air in the solution was replenished with nitrogen gases and the vials or ampoules were sealed, followed by storage in a cold dark place.

Example No. 19:

30 This example provided the injectable preparations for curing the affected abnormal tissues for use in site, which contained the components as follows:

Agent I:

35	Tannic acid	15 mg
	Sodium hydrogen sulfite	15 mg
	Injectable distilled water	To make 10 ml

This Sheet Has Been Replaced



Agent II:

	Aluminum potassium sulfate	400 mg
	Sodium citrate	150 mg
	Dextran 40	70 mg
5	Glycerin	1,000 mg
	Injectable distilled water	To make 10 ml

The above Agent I was prepared by adding the total amount of tannic acid in the presence of nitrogen gases to a solution prepared by dissolving sodium hydrogen sulfite in the injectable distilled water. On the other hand, the above agent II was prepared by dissolving sodium citrate in the injectable distilled water in the presence of nitrogen gases and adding thereto aluminum potassium sulfate in the presence of nitrogen gases, followed by addition thereto of dextran and glycerin. The Agents I and II prepared in the above manner were combined into injectable preparations for use in site by adding the Agent II to the Agent I. The injectable preparations were adjusted with sulfuric acid to a pH of 2.7.

20 Example No. 20:

This example provided the injectable preparations for curing the affected abnormal tissues for use in site which contained the components as follows:

Agent I:

25	Aluminum potassium sulfate	400 mg
	Sodium citrate	150 mg
	Sodium hydrogen sulfite	20 mg
	Injectable distilled water	To make 10 ml

Agent II:

30	Tannic acid	20 mg
	Glycerin	1,200 mg
	Injectable distilled water	To make 10 ml

The above Agent I was prepared by adding the total amounts of sodium hydrogen sulfite and sodium citrate in the presence of nitrogen gases to the injectable distilled water and then aluminum potassium



sulfate to the resulting solution in the presence of nitrogen gases. Separately, the above agent II was prepared by dissolving glycerin and tannic acid in this order in the injectable distilled water in the presence of nitrogen gases. The Agents I and II prepared in the manner as described hereinabove were combined in site for use as injectable preparations by adding the Agent II to the Agent I. The injectable preparations were adjusted with sulfuric acid, as needed, to a pH of 2.7.

Example No. 21:

This example provided the injectable preparations for curing the affected abnormal tissues for use in site which contained the components as follows:

Agent I:

Aluminum potassium sulfate	400 mg
Sodium citrate	150 mg
Injectable distilled water	To make 10 ml

Agent II:

Tannic acid	50 mg
Sodium hydrogen sulfite	100 mg
Injectable distilled water	To make 10 ml

The above Agent I was prepared by adding the total amount of sodium citrate to the injectable distilled water and then aluminum potassium sulfate to the resulting solution in the presence of nitrogen gases. On the other hand, the above agent II was prepared by dissolving sodium hydrogen sulfite and tannic acid in the injectable distilled water in the presence of nitrogen gases. The above Agent III was prepared in substantially the same manner as above by dissolving sodium hydrogen sulfite in the presence of nitrogen gases in the injectable distilled water. The Agents I and II prepared in the above manner were used as injectable preparations by adding the Agent II to the Agent I. The injectable preparations were adjusted to a pH of 2.7.

Example No. 22:



This example provided the injectable preparations for curing the affected abnormal tissues for use in site which contained the components as follows:

Agent I:

5	Aluminum potassium sulfate	400 mg
	Sodium citrate	150 mg
	Tannic acid	15 mg
	Sodium hydrogen sulfite	15 mg
	Injectable distilled water	To make 10 ml

10 Agent II:

	Glycerin	1,000 mg
	Dextran	70 mg
	Injectable distilled water	To make 10 ml

The above Agent I was prepared by adding the
15 total amount of sodium citrate to the injectable distilled water and then aluminum potassium sulfate to the resulting solution in the presence of nitrogen gases. To the resulting solution was added a solution prepared by dissolving the total amounts of sodium hydrogen sulfite
20 and tannic acid in the injectable distilled water in the presence of nitrogen gases. The resulting Agent I had a pH of 2.7 and was lyophilized in conventional manner, followed by storage for one month in a cold dark place.

The injectable preparations were prepared for
25 use in site by adding the Agent II to the Agent I and used for tests for stability of the preparations in a way as will be described hereinafter.

Comparative Example No. 1:

The composition prepared in Example No. 1 was
30 adjusted with sodium hydroxide to pH4.7 for comparative purposes.

Comparative Example No. 2:

The composition was prepared by adding dextran, aluminum potassium sulfate, glycerin and tannic acid in
35 this consecutive order in the injectable distilled water in the presence of nitrogen gases. The resulting inject-



able preparations were adjusted with sulfuric acid to pH2.7.

Comparative Example No. 3:

5 The injectable preparations of this comparative example was prepared which contained the following components:

	Aluminum potassium sulfate	4.0 g
	Tannic acid	0.15 g
	Sodium citrate	1.5 g
10	Dextran	10 ml
	Trichlorobutanol	0.5 g
	Glycerin	10 ml
	Injectable distilled water	To make 100 ml

15 The injectable preparations were prepared by adding each of the above components to the injectable distilled water in the manner as enumerated hereinabove and the resulting preparations were adjusted with sodium hydroxide to pH4.7.

Comparative Example No. 4:

20 The sclerosing agent having the same composition as disclosed in Japanese Patent Unexamined Publication (Kokai) No. 4-225,920 as the Comparative Preparation Formulation Example No. 1 was prepared in substantially the same manner as disclosed in this publication. More
25 specifically, the composition having the same components was formulated in the same order and in substantially the same manner as disclosed in this publication to give injectable preparations which were then adjusted with sodium hydroxide to pH4-5. The resulting injectable
30 preparations were filled by a 10 ml portion in each of colorless hard glass ampoules which in turn were treated in order to replenish the air in the ampoules with nitrogen gases and then sterilized with high pressure steam in conventional manner.

35 Comparative Example No. 5:

The sclerosing agent having the same composition

This Sheet Has Been Replaced



as disclosed in Japanese Patent Unexamined Publication (Kokai) No. 4-225,920 as the Comparative Preparation Formulation Example No. 2 was prepared in substantially the same manner as disclosed in this publication. More specifically, the composition having the same components was formulated in substantially the same manner as disclosed in this publication to yield injectable preparations which were then adjusted with sodium hydroxide to pH4-5. The resulting injectable preparations were filled by a 10 ml portion in each of colorless hard glass ampoules which in turn were treated in order to replenish the air in the ampoules with nitrogen gases and then sterilized with high pressure steam in conventional manner.

15 Comparative Example No. 6:

The sclerosing agent having the same composition as disclosed in Japanese Patent Unexamined Publication (Kokai) No. 4-225,920 as the Comparative Preparation Formulation Example No. 5 was prepared in substantially the same manner as disclosed in the publication. More specifically, the composition having the same components was formulated in the same order and in substantially the same manner as disclosed in the publication to give the composition which was then adjusted with sulfuric acid to pH2.7. The resulting aqueous solution was filled by a 50 ml portion in each of colorless hard glass vials which in turn were treated in order to replenish the gases in the vials with nitrogen gases and then sterilized with high pressure steam in conventional manner.

30 Comparative Example No. 7:

Into a test tube were poured simultaneously the same components in the same amounts as Example No. 1, and injectable distilled water was added with stirring to the mixture to make the total amount 10 ml. The resulting solution became turbid in white color and caused precipitating as the time passed by.



Comparative Example No. 8:

The same amounts of the same components as indicated in Example No. 1 above were dissolved with stirring in the same order in injectable distilled water. The resulting solution became turbid in white color and caused precipitating as the time has elapsed.

Comparative Example No. 9:

The same amounts of the same components as indicated in Example No. 1 above were dissolved with stirring in the same order in injectable distilled water. The resulting solution became turbid in white color and caused precipitating as the time has passed by.

Comparative Example No. 10:

For the preparation of the composition having the same components and containing the same amounts, respectively, as Example No. 1 above, dextran and glycerin were admixed with injectable distilled water, followed by the addition of aluminum potassium sulfate and tannic acid to the resulting mixture. To the resulting solution were added sodium citrate and sodium hydrogen sulfite to give injectable preparations. It was found that this solution turned turbid in white color at the time when tannic acid was added and it soon caused precipitates in a dark brown color.

Comparative Example No. 11:

A solution (Agent I) was prepared by dissolving 400 mg of aluminum potassium sulfate and 400 mg of tannic acid in 10 ml of injectable distilled water in the presence of nitrogen gases. Separately, a solution (Agent II) was prepared by dissolving 70 mg of dextran, 1,000 mg of glycerin, 15 mg of sodium citrate and 15 mg of sodium hydrogen sulfite in this order in 10 ml of injectable distilled water in the presence of nitrogen gases. The injectable preparations were prepared by admixing Agent I with Agent II. The injectable preparations were found to turn turbid in pale brown color at the time when tannic



acid was added to aluminum potassium sulfate in the Agent I and the resulting solution caused precipitates in dark brown color within short.

5 The injectable preparations prepared in the manner as described hereinabove were subjected to tests for stability of preparations.

Tests for Stability of Preparations:

10 After the injectable preparations prepared in the above-mentioned Examples were adjusted to give the pH ranges as defined hereinabove, five colorless hard glass vials were aseptically filled with 10 ml of each of the compositions and the air in the vials was replenished with nitrogen gas under vacuum conditions. The vials were then exposed to white light with 1,000 lux at 40° C and visual
15 observations were made as to coloring and the extent of depositing. Before carrying out the tests for stability of injectable preparations, each of the compositions was found colorless or transparent, yellowish and slightly viscous. The test results are shown in Table 1 below.

20

This Sheet Has Been Replaced





TABLE 1: Tests for Stability of Preparations

Prepara- tions Example Nos.	Storage Period of Time (Months)					
	0	1	2	3	6	12
1	Colorless or faintly yellowish	Colorless or faintly yellowish	Colorless or faintly yellowish	Colorless or faintly yellowish	Colorless or faintly yellowish	Colorless or faintly yellowish
5	-do-	-do-	-do-	-do-	-do-	-do-
6	-do-	-do-	-do-	-do-	-do-	-do-
7	-do-	-do-	-do-	-do-	-do-	-do-
8	-do-	-do-	-do-	-do-	-do-	-do-
9	Pale yellow	Pale yellow	Pale yellow	Pale yellow	Pale yellow	Pale yellow
10	-do-	-do-	-do-	-do-	-do-	-do-
11	-do-	-do-	-do-	-do-	-do-	-do-
12	-do-	-do-	-do-	-do-	-do-	-do-
13	-do-	-do-	-do-	-do-	-do-	-do-
14	-do-	-do-	-do-	-do-	-do-	-do-
15	-do-	-do-	-do-	-do-	-do-	-do-
16	-do-	-do-	-do-	-do-	-do-	-do-
17	-do-	-do-	-do-	-do-	-do-	-do-

5

10

15

20



34

18	-do-	-do-	-do-	-do-	-do-	-do-
19	-do-	-do-	-do-	-do-	-do-	-do-
20	-do-	-do-	-do-	-do-	-do-	-do-
21	-do-	-do-	-do-	-do-	-do-	-do-
22	-do-	-do-	-do-	-do-	-do-	-do-
Compara- tive Example 1	Colorless or faintly yellowish	White deposit	White deposit	White deposit	White deposit	White deposit
Compara- tive Example 2	-do-	Colored deposit	Colored deposit	Colored deposit	Colored deposit	Colored deposit
Compara- tive Example 3	-do-	White deposit	White deposit	Colored deposit	Colored deposit	Colored deposit
Compara- tive Example 4	-do-	Colored deposit	Colored deposit	Colored deposit	-do-	-do-
Compara- tive Example 5	-do-	-do-	-do-	-do-	-do-	-do-

5

10

15

20

25

Compara- tive Example 6	-do-	-do-	-do-	-do-	-do-	-do-
Compara- tive Example 7	-do-	-do-	-do-	-do-	-do-	-do-
Compara- tive Example 8	-do-	-do-	-do-	-do-	-do-	-do-
Compara- tive Example 9	-do-	-do-	-do-	-do-	-do-	-do-
Compara- tive Example 10	-do-	-do-	-do-	-do-	-do-	-do-
Compara- tive Example 11	Pale brown	-do-	-do-	-do-	-do-	-do-

5

10

15

20

25



Table 2 below shows the results of the tests for stability of the injectable preparations in substantially the same manner as in Table 1 above with the exception that the temperature for storage was set to 60°C.

5

This Sheet Has Been Replaced



TABLE 2: Tests for Stability of Preparations

Prepara- tions Example Nos.	Storage Period of Time (Months)					
	0	1	2	3	6	12
1	Colorless or faintly yellowish	Colorless or faintly yellowish	Colorless or faintly yellowish	Colorless or faintly yellowish	Colorless or faintly yellowish	Colorless or faintly yellowish
2	-do-	-do-	-do-	-do-	-do-	-do-
3	-do-	-do-	-do-	-do-	-do-	-do-
4	-do-	-do-	-do-	-do-	-do-	-do-
8	-do-	-do-	-do-	-do-	-do-	-do-
9	Pale yellow	Pale yellow	Pale yellow	Pale yellow	Pale yellow	Pale yellow
10	-do-	-do-	-do-	-do-	-do-	-do-
11	-do-	-do-	-do-	-do-	-do-	-do-
12	-do-	-do-	-do-	-do-	-do-	-do-

5

10

15

This Sheet Has Been Replaced



A description will made of experiments for the cytotoxic action of the compositions for curing the affected abnormal tissues according to the present invention.

5 For the injectable preparations obtained in Example No. 1, a comparative review of the cytotoxic effects was made using the endothelial cells of the venous vessel of the human funiculus (primary culture), the fibroblast of the human normal diploid (primary culture)
10 and the rat muscle blast cells (cell culture). As comparative chemicals, there were employed Paoscle™ (containing phenol as a major active ingredient) as an agent for sclerosing the internal piles and Oldamin™ (containing monoethanolamine oleate as a major active ingredient),
15 Aethoxysklerol™ (containing polidocanol as a major active ingredient) and ethanol (containing ethanol as a major active ingredient) as agents for sclerosing esophageal varix.

20 The method for determining the death of the cells was based on the trypan blue dyeing method.
Experiment No. 1:

 The method for experiment was as follows.

 Each kind of the cells was inoculated at the rate of 5×10^3 cells per dish. A 1:1 mixture of 2%
25 procaine hydrochloride and a test agent which was diluted to a 100-fold or 1,000-fold dilution with a cell culture solution (a 0.5% sodium chloride solution) was prepared. To the inoculant was added the dilution, and the resulting mixture was supplied with a 1:1 mixture of DMEM and HAM
30 F12 and a 10% fetal bovine serum. The test cells were then cultured in 5% CO₂ at 37°C.

 The resulting culture liquid was digested with trypsin to give a cells floating solution to which an equal amount of the test agent was added. This mixture was
35 allowed to stand for 10 minutes at 37°C and the equal volume of a 0.3% trypan blue solution was added thereto.



The number of the living cells (not dyed with trypan blue) and the dead cells (dyed with trypan blue) were counted in 15 minutes after addition of the trypan blue solution.

As a control, there was used a 0.9% sodium chloride solution (a solution obtained by adding 5% fetal bovine serum to the cells floating solution used for test).

The test results are shown in Table 3 below.

TABLE 3: RATES OF LIVING CELLS

TEST AGENTS	RATES OF LIVING CELLS (%)		
	CELL 1	CELL 2	CELL 3
COMPOSITION OF THE PRESENT INVENTION	96.8	90.3	95.0
PAOSCLE™	79.8	89.3	87.0
OLDAMIN™	0.0	0.0	0.0
AETHOXYSKLEROL™	0.0	0.0	0.0
ETHANOL	0.0	0.0	0.0
CONTROL (0.9% SODIUM CHLORIDE SOLUTION)	97.0	91.7	94.0

NOTES: CELL 1: Endothelial cells of the venous vessel of the human funiculus (primary culture)

CELL 2: Fibroblast of the human normal diploid (primary culture)

CELL 3: Rat muscle blast cells (cell culture)

As is apparent from the test results as shown in Table 3 above, the 0.9% sodium chloride solution used as the control and Paoscle™ did not cause killing a majority of the cells tested, while Oldamin™, Aethoxysklerol™ and ethanol used as the agent for sclerosing the esophageal varix caused the entire number (100%) of the cells.

Among the living cells used in the above tests,

This Sheet Has Been Replaced



the fibroblast of the human normal diploid was cultured again. More specifically, the living cells were washed and inoculated in a culture medium solution containing the same culture medium as used before, followed by the culture at 37°C for 24 hours. As a result, it was found that no living cells were counted at all out of the cells exposed to the composition according to the present invention, on the one hand, and that 95% of the cells were found alive and kept growing out of the cells treated with the 0.9% sodium chloride solution and 80% of the cells were alive and kept growing out of the cells treated with Paoscle™, on the other hand.

Experiment No. 2:

The experiment was carried out in substantially the same manner as in Experiment No. 1 above, with the exception that a 2% xylocaine hydrochloride solution was used for the 1:1 mixture of the test agent added to the liquid cell culture medium in place of the 2% procaine hydrochloride solution. It was found as a result of re-culture that the total number (100%) of the fibroblast of the human normal diploid cultured again were dead.

Experiment No. 3:

The experiment was carried out in substantially the same manner as in Experiment No. 1 above, with the exception that the test chemical alone was added to the cell culture medium (0.9% sodium chloride solution + 5% fetal bovine serum). It was found as a result of re-culture that the total number (100%) of the fibroblast of the human normal diploid cultured again were dead.

Experiment No. 4:

The experiment was carried out in substantially the same manner as in each of the experiment Nos. 1, 2 and 3 above, with the exception that the re-culture was conducted in a liquid cell culture medium to which no 5% fetal bovine serum was not added. It was found as a result of re-culture that the total number (100%) of the fibro-



blast of the human normal diploid exposed to the composition according to the present invention were dead, while it was found that no cells were killed by the liquid cell culture medium (0.9% sodium chloride solution) used as the control.

INDUSTRIAL UTILIZATION OF THE INVENTION

The compositions according to the present invention are constant and stable in formulation as well as effective for curing the affected abnormal tissues of the digestive system, particularly the large intestine and rectum, because the compositions comprising substantially the water-soluble aluminum compound, the chelating agent, tannic acid and sodium hydrogen sulfite are adjusted within a pH range of from pH1.0 to pH3.5 in such a manner that tannic acid does not react with the metal ions, such as aluminum ions, derived from the water-soluble aluminum compound and no formation of precipitates are caused.

Further, the compositions for curing the affected abnormal tissues according to the present invention can be made more stable in formulation by adding the polyvalent alcohol and/or saccharide, as needed, to the compositions substantially comprising the water-soluble aluminum compound, the chelating agent, tannic acid and sodium hydrogen sulfite.

In addition, in preparing the compositions for curing the affected abnormal tissues according to the present invention, tannic acid is prevented from causing precipitating as a result of its reaction with the metal ions, such as aluminum ions, decomposed from the water-soluble aluminum compound, by adding it to a formulation consisting substantially of the water-soluble aluminum compound, the chelating agent and sodium hydrogen sulfite, whereby the stable compositions having the constant formulation can be prepared.

Furthermore, it is noted that the admixture of

This Sheet Has Been Replaced



a first formulation comprising the water-soluble aluminum compound and the chelating agent with a second formulation comprising tannic acid and sodium hydrogen sulfite can lead to the preparation of the compositions according to the present invention, which can offer the advantages in preparing the compositions for curing the affected abnormal tissues according to the present invention that the reaction of tannic acid with the metal ions such as aluminum ions decomposed from the water-soluble aluminum compound can be controlled more readily so as to cause no precipitating.

It is further advantageous that the optional addition of the polyvalent alcohol and/or saccharide to the compositions consisting substantially of the water-soluble aluminum compound, the chelating agent, tannic acid and sodium hydrogen sulfite can contribute greatly to making the compositions more stable and preparing the compositions in a ready way because the timing of the addition can be chosen in an optional way.

Furthermore, in preparing the compositions according to the method according to the present invention, it is extremely advantageous to enable the pH range of the compositions for curing the affected abnormal tissues to be adjusted at an appropriate stage of formulation of each of the components, particularly in terms of making it easy to prevent tannic acid from being oxidized and making it to prevent tannic acid from being reacted with the metal ions derived from the water-soluble aluminum compound.

The present invention can offer the further advantage that the compositions according to the present invention can be made stable in formulation by formulating each of the components at an appropriate stage under atmosphere of inert gases.

Likewise, it is beneficial in preparing the stable compositions for curing the affected abnormal



tissues according to the present invention having the constant and stable formulation that each of the components is formulated under the condition under which no substantial amount or an extremely limited amount of oxygen exists in an atmosphere or in a liquid state because the such condition can contribute particularly to a prevention of tannic acid from being oxidized.

In addition, it is very beneficial in preparing the stable compositions for curing the affected abnormal tissues according to the present invention having the constant formulation that a solution containing the polyvalent alcohol and/or saccharide can be added to or mixed with the first formulation comprising the water-soluble aluminum compound and the chelating agent and/or the second formulation comprising tannic acid and sodium hydrogen sulfite or a mixture of the first formulation with the second formulation immediately before administration, because this way of preparing the injectable preparations can prevent each of the components from being changed or transformed according to a lapse of time.

The compositions according to the present invention can offer the further advantage that the injectable preparations can be stored in a stable state for a long period of time because it is possible to adjust the pH range of the compositions after all the components have been formulated. In addition, it is beneficial for stabilizing the compositions for a long period of time that the compositions can be stored under atmosphere of inert gases.

This Sheet Has Been Replaced





C L A I M S

1. A composition for curing affected abnormal tissues characterized in that said composition comprises substantially a water-soluble aluminum compound, tannic acid, sodium hydrogen sulfite and a chelating agent and that a pH range of said composition is adjusted to from pH1.0 to pH3.5.

2. A composition for curing affected abnormal tissues as claimed in claim 1, further comprising containing a polyvalent alcohol and/or a saccharide.

3. A composition for curing affected abnormal tissues as claimed in claim 1 or 2, wherein said water-soluble aluminum compound is selected from aluminum chloride, aluminum sulfate, aluminum carbonate, aluminum acetate, aluminum nitrate, aluminum lactate, aluminum tartrate, aluminum salicylate, aluminum sodium sulfate, aluminum potassium sulfate, aluminum cesium sulfate and aluminum ammonium sulfate.

4. A composition for curing affected abnormal tissues as claimed in claim 1, 2 or 3, wherein said water-soluble aluminum compound is contained at a rate of from 1% to 10% as an effective concentration in preparations.

5. A composition for curing affected abnormal tissues as claimed in any one of claims 1 to 4, wherein said tannic acid is contained at a rate of from 0.01% to 2.0% as an effective concentration in preparations.

6. A composition for curing affected abnormal tissues as claimed in any one of claims 1 to 5, wherein said chelating agent is citric acid or a salt thereof.

7. A composition for curing affected abnormal tissues as claimed in claim 6, wherein said chelating agent is contained at a rate of from 10% to 80% with respect to the amount of said water-soluble aluminum compound.

8. A composition for curing affected abnormal





tissues as claimed in any one of claims 1 to 7, wherein said sodium hydrogen sulfite is contained at a rate of from 50% to 200% with respect to the amount of said tannic acid.

5 9. A composition for curing affected abnormal tissues as claimed in claim 8, wherein said sodium hydrogen sulfite is contained at a rate of from 70% to 150% with respect to the amount of said tannic acid.

10 10. A composition for curing affected abnormal tissues as claimed in claim 2, wherein said polyvalent alcohol and/or said saccharide is selected from mannitol, fructose, xylitol, glucose, galactose, mannose, lactose and glycerin.

15 11. A composition for curing affected abnormal tissues as claimed in claim 10, wherein said polyvalent alcohol and/or said saccharide are or is contained at a rate of from 3% to 20% as an effective concentration in preparations.

20 12. A composition for curing affected abnormal tissues as claimed in any one of claims 1 to 11, wherein said pH range is set to be from pH2.0 to pH3.0.

25 13. A method for the preparation of a composition for curing affected abnormal tissues comprising substantially a water-soluble aluminum compound, a chelating agent, tannic acid and sodium hydrogen sulfite and having a pH of said composition set to range from pH1.0 to pH3.5, characterized in that tannic acid is added to a mixture prepared by formulating said water-soluble aluminum compound, said chelating agent and said sodium
30 hydrogen sulfite in an optional order.

35 14. A method for the preparation of a composition for curing affected abnormal tissues as claimed in claim 13, wherein a polyvalent alcohol and/or a saccharide is added to said mixture prepared by formulating said sodium hydrogen sulfite, said water-soluble aluminum compound and/or said chelating agent.





15. A method for the preparation of a composition for curing affected abnormal tissues as claimed in claim 13 or 14, wherein a pH range of said mixture to which said tannic acid is added is adjusted to said pH range, as needed.

16. A method for the preparation of a composition for curing affected abnormal tissues characterized in that a first formulation is prepared by mixing a water-soluble aluminum compound with a chelating agent, a second formulation is separately prepared by mixing tannic acid with sodium hydrogen sulfite, and said first formulation is admixed with said second formulation to yield said composition.

17. A method for the preparation of a composition for curing affected abnormal tissues as claimed in claim 16, wherein a polyvalent alcohol and/or a saccharide are or is added to each of said first formulation and said second formulation or either one of said first formulation and said second formulation or to a mixture of said first formulation with said second formulation.

18. A method for the preparation of a composition for curing affected abnormal tissues as claimed in claim 16 or 17, wherein a pH range of each of said first and second formulations or either one of said first and second formulation or a mixture of the first and second formulations is adjusted, as needed, to said pH range.

19. A method for the preparation of a composition for curing affected abnormal tissues as claimed in any one of claims 13 to 18, wherein each of components constituting said composition or either of said components is formulated with each other under inert atmosphere.

20. A method for the preparation of a composition for curing affected abnormal tissues as claimed in any one of claims 13 to 19, wherein oxygen exists in atmosphere or in water to be used in no substantial amount or at such a restricted amount as failing to adversely





affect said composition.


21. A method for the preparation of a composition for curing affected abnormal tissues as claimed in any one of claims 13 to 20, wherein a pH of said composition is adjusted as needed to said pH range after all of said components constituting said composition have been formulated.

22. A method for the preparation of a composition for curing affected abnormal tissues as claimed in any one of claims 13 to 21, wherein said composition is filled under inert atmosphere in a container for injection or a container for storing injectable preparations.

23. Use of a composition for curing affected abnormal tissues comprising substantially a water-soluble aluminum compound, a chelating agent, tannic acid and sodium hydrogen sulfite and having a polyvalent alcohol and/or saccharide added as needed to said composition as well as having a pH range of said composition adjusted to from pH1.0 to pH3.5, characterized in that said composition is applied to kill cells of the affected abnormal tissues to thereby cure diseases caused by the affected abnormal tissues.

24. Use of a composition for curing affected abnormal tissues as claimed in claim 23, wherein said composition is applied to cure piles or hemorrhoids, uplift affected tissues of the digestive system or hepatic tumor.

25. Use of a composition for curing affected abnormal tissues as claimed in claim 23 or 24, wherein said composition is applied in the form of an injection.



A B S T R A C T

Injectable preparations of the composition for curing affected abnormal tissues are prepared by formulating sodium hydrogen sulfite with all the other components except tannic acid to yield a first mixture and adding tannic acid to the first mixture or by formulating a water-soluble aluminum compound and a chelating agent to yield a first formulation, formulating tannic acid and sodium hydrogen sulfite to yield a second formulation and admixing the first formulation with the second formulation to yield a second mixture and, as needed, adding a polyvalent alcohol and/or a saccharide to the first and/or second formulations or to the first or second mixture. This preparation can prevent tannic from being oxidized and from reacting directly with an aluminum ion derived from sodium hydrogen sulfite, whereby the composition having a stable formulation can be provided.

The resulting compositions for curing the affected abnormal tissues is stable in quality and constant in formulation.

This Sheet Has Been Replaced



REPLACEMENT SHEETS		SG
☒	Description : paged to paged	..
☒	Claim(s) : paged	..
☐	Drawing(s) : paged to paged	..
☒	Abstract : paged	..
DATE OF RECEIPT 7/10/96		

1

DESCRIPTION

TITLE OF THE INVENTION

5 COMPOSITIONS FOR CURING AFFECTED
ABNORMAL TISSUES, METHOD FOR THE PREPARATION THEREOF,
AND USAGE THEREOF

TECHNICAL BACKGROUND

10 The present invention relates to a composition
for curing affected abnormal tissues, a method for the
preparation thereof, and usage thereof and, more parti-
cularly, to a composition for curing affected abnormal
tissues caused, for example, by piles or hemorrhoids and
15 the like, which is stable during storage for a long period
of time, a method for the preparation of the composition
therefor, and usage for curing such affected abnormal
tissues by using the composition therefor.

20 BACKGROUND ART

Injection therapy of internal piles or hemor-
rhoids has a history of more than 100 years. The early
injections used for the such therapy were composed of a
ferrous sulfate solution, phenol in olive oil, and the
25 like. Thereafter, there were used alcohol, quinine
hydrochloride, mercuric chloride, urethan, ergot and the
like. In the past thirty years, a phenol solution in
vegetable oil and an alum solution have been used most
frequently for curing the internal piles or hemorrhoids.

30 These compositions, however, cannot be said to
satisfactorily solve all or most of such problems for
curing internal piles or hemorrhoids for reasons as will
be described hereinafter. It is noted that the injection
therapy for sclerosing the internal piles or hemorrhoids
35 requires for the injectable preparations to reduce inflam-
mation, to stop bleeding, to inhibit the growth of

REPLACED SHEETS		SG
☒	Description : paged 477-478 to paged	..
☒	Claim(s) : paged	..
☐	Drawing(s) : paged to paged	..
☐	Abstract : paged to paged	..
DATE OF RECEIPT		Date:

This is the replacement sheet

7 OCT 1996

bacteria, to bring about well-formed thrombosis and to complete fibrosis of hemorrhoidal blood vessels without leaving any hard nodules or causing necrosis. The injectable preparations so far developed for curing the internal piles or hemorrhoids by sclerosing the affected abnormal tissues of the digestive system, however, do not satisfy any or a majority of the requirements as described immediately hereinabove. It is also noted as difficult to determine the appropriate concentration and quantity of the injectable preparations used at clinical needs, as well as a procedure to sclerose the internal piles or hemorrhoids without causing necrosis. It is further required that the methods of injection therapy and administration be improved so as to expand the injected area because the composition be deposited only in the submucosa when injected.

As a composition for curing internal piles or hemorrhoids, there is proposed an injectable agent that comprises tannin, alum, sodium citrate, dextran, glycerin and trichlorobutyl alcohol (Journal of Traditional Chinese Medicine: vol. 1, No. 2, pp. 116-120 (1981)). Alum has a chemical nomenclature as aluminum potassium sulfate and it is a colorless and transparent substance of an octahedral crystal. It has locally astringent, hemostatic and antiseptic properties. Alum is not absorbed through the gastroenteric mucosa when administered internally and exerts merely a local action against the mucosa. On the other hand, tannic acid is usually obtained from nutgall or gall and may be a yellow-white or pale brown, amorphous and powdery substance or a small-leaf-shaped or spongy bulky substance. Tannic acid can cause a protein to coagulate in an acidic or neutral solution and has astringent, antiseptic and anti-bacterial properties.

It is further noted that aluminum potassium sulfate is not allowed to be practically used in combination with tannic acid or tannin agents (Pharmacopedia

Japonica, The 12th Revision (1991); pp. D-1019-1021). In addition, it is also known that tannic acid forms a less soluble salt with basic organic chemical substances and a non-soluble or sparingly soluble compound with an iron agent or the like, thereby losing its effects.

The injectable preparations as described immediately hereinabove contains trichlorobutyl alcohol so that there is the possibility that it presents the problems as will be described hereinafter. It is known that trichlorobutyl alcohol is a compound in which carbon atoms and chlorine atoms are combined with each other and it can oxidize tannic acid due to the formation of a radical upon the absorption of light, thereby causing tannic acid to turn into precipitated materials having a brown or black color. Further, trichlorobutyl alcohol has the property that the linkage between the carbon and chlorine atoms is broken upon application of high energy such as heat or light, turning into unstable substances. It is thus said to be inappropriate to use trichlorobutyl alcohol as a component of a medicine due to its such property because there is the highly probable risk that it causes precipitates in the injectable preparations during storage. In addition, the use of such a compound is less convenient in handling and storing because the greatest possible care is required for storing the injectable preparations containing it.

Further, Japanese Patent Unexamined Publication Kokai No. 4-225,920 discloses an agent for hardening or sclerosing the affected abnormal tissues of the digestive system such as, for example, esophagophlebangioma, piles or hemorrhoids, rectal prolapse, prolapse of the rectal mucosa and the affected uplift tissues of the large intestine and the rectum. The sclerosing agent consists of a composition comprising tannic acid, aluminum potassium sulfate and a stabilizing agent including an extract of a medicinal plant, containing a phenol, a flavone or a

This is the replacement sheet

Date: 7 OCT 1996



flavonoid, a catechin or a polycarboxylic acid. As this composition contains the extract of the medicinal plant as the stabilizing agent, however, it suffers from the disadvantages in terms of formulating preparations that it is extremely difficult to provide injectable preparations with a constant formulation and stable quality as well as that there is still the possibility that the stabilizing agent may be contaminated with minute amounts of unidentified substances even if it would be extracted and purified elaborately through plural steps. It has further been found that such a composition comprising tannic acid and aluminum potassium sulfate may cause coloring or, in some cases, precipitating, even if it contains the extract of the plant as a stabilizing agent, when stored for a long period of time in a liquid state. This also may cause the problem when it is applied as an injectable agent.

In addition, PCT International Publication No. W094/06443 (International Publication Date: March 31, 1994) discloses a composition for curing affected abnormal tissues of the digestive system as injectable preparations, which comprises a composition containing a water-soluble aluminum compound in a concentration ranging from 0.01 mole to 0.5 mole, tannic acid at a rate of 0.5% to 25.0% with respect to the amount of the water-soluble aluminum compound, sodium hydrogen sulfite, and a polyvalent alcohol or a saccharide; in which a pH of said composition is adjusted so as to become in the range of from pH1.5 to pH3.5. The components of the compositions disclosed in this publication are the same as those of the ones to which the present invention is directed. This publication, however, discloses a method for the preparation of the composition for curing the affected abnormal tissues of the digestive system as well as the compositions consisting of the same components as those of the present invention. The published method comprises formu-

lating all the components of the composition in a simultaneous way or in a random way. More specifically, the method for the preparation of the hardening or sclerosing agent disclosed in this publication comprises placing all the components in a test tube, pouring a predetermined amount of distilled water for injection use with stirring in the test tube, and dissolving them to give an aqueous solution. The resulting aqueous solution is then filled in a container such as a glass bottle, followed by removal of oxygen dissolved in the solution and replenishment of air with nitrogen gases. Thereafter, the solution is sterilized with high-pressure steam and then stored in a cold and dark place. It has been found, however, that the general method for the formulation of the composition as disclosed in this publication suffers from the extreme difficulty in preparing a stable composition with the constant formulation and that it presents the problem in the actual preparation of the compositions as an injectable agent.

Aluminum potassium sulfate, which may also be called alum and is used as one component for the composition according to the present invention, has been applied as an a hemostatic agent. As described hereinabove, however, a combination of aluminum potassium sulfate with a tannic agent is prohibited to be used as medicine as set forth in Pharmacopedia Japonica. Nevertheless, various attempts have been made to use aluminum potassium sulfate in combination with the tannic agent as medicine; however, aluminum potassium sulfate is very unstable when it is mixed with the tannic agent as it is because it may be caused to become colored or to precipitate. Hence, the use of such an unstable composition as injectable preparations is inappropriate even in terms of safety.

Further, aluminum potassium sulfate usually contains a small amount of iron because it is prepared

This is the replacement sheet.

Date: 7 OCT 1996

from bauxite as a raw material. Pharmacopedia Japonica regulates the acceptable contents of iron derivatives to be 20 ppm or less when aluminum potassium sulfate is employed as a raw material for medicine.

5 In addition, aluminum potassium sulfate may be caused to be decomposed into aluminum ions such as Al^{3+} , $\text{Al}(\text{OH})^{2+}$, $\text{Al}(\text{OH})^+$ and the like upon dissociation in a solution and react with hydroxyl ion, OH^- , to form aluminum hydroxide, $\text{Al}(\text{OH})_3$, which are caused to precipitate in
10 a solution. If such precipitates are formed in the solution, it is inappropriate to employ it as a composition for injectable preparations and it cannot be applied for treatment.

 On the other hand, tannic acid is oxidized to
15 form an oxide compound such as a quinone compound upon exposure to oxygen existing in air or dissolved in a solution to be used, thereby causing precipitates when the solution is used for injectable preparations. If such insoluble products are caused to precipitate in the
20 injectable preparations, the resulting injection becomes as a matter of course inappropriate as medicine and cannot be administered.

 Further, tannic acid is caused to be oxidized forming precipitates, particularly when iron ions are
25 present in the solution. Hence, if tannic acid exists with aluminum potassium sulfate in the solution, the iron ions present in the aluminum potassium sulfate contained in the solution are reacted directly with tannic acid, leading to the formation of precipitates, and the oxidation of
30 tannic acid is accelerated.

 In addition, tannic acid is allowed to react directly with aluminum ions, causing to form precipitates, if the aluminum ions are present in the solution, and it is likely to undergo oxidation.

35 Accordingly, a composition containing aluminum potassium sulfate and tannic acid cannot be prepared in

This is the replacement sheet

Date: 7 OCT 1996



a constant and stable manner without causing any precipitates simply by formulating all the components in a simultaneous or random way.

As the result of a detailed review on the order and conditions of formulating the components in preparing the preparations for injection, it has been found by the present inventor that the injectable preparations for curing the affected abnormal tissues having a constant and stable composition can be prepared by arranging the order of formulation of its components and the concentrations thereof. Thus, the present invention has been completed from this finding.

DISCLOSURE OF INVENTION

Therefore, the present invention can solve the problems involved in conventional compositions for curing the affected abnormal tissues and the present invention has the objects to provide an composition for curing the affected abnormal tissues with improved effects, to provide a method for the production of the injectable preparations having a constant and stable formulation, and to provide the use of the composition for application in order to cure piles or hemorrhoids, affected uplift tissues of the digestive tracts, hepatic tumor, and the like.

The composition for curing the affected abnormal tissues in accordance with the present invention may comprise substantially a water-soluble aluminum compound, tannic acid, a chelating agent, and sodium hydrogen sulfite. The pH range of the composition is adjusted to be from pH1.0 to pH3.5.

Alternatively, the composition for curing the affected abnormal tissues according to the present invention may further comprise the polyvalent alcohol and/or saccharide in addition to the formulation consisting of the water-soluble aluminum compound, the chelating



agent, tannic acid and sodium hydrogen sulfite, the composition being adjusted, as needed, to a pH ranging from pH1.0 to pH3.5.

5 As the water-soluble aluminum compound to be employed for the composition for curing the affected abnormal tissues in accordance with the present invention, there may be mentioned, for example, aluminum chloride, aluminum sulfate, aluminum carbonate, aluminum acetate, aluminum nitrate, aluminum lactate, aluminum tartrate,
10 aluminum salicylate, aluminum sodium sulfate, aluminum potassium sulfate, aluminum cesium sulfate, ammonium aluminum sulfate and the like. The water-soluble aluminum compounds may be applied singly or in combination of two or more.

15 The water-soluble aluminum compound may be formulated in concentrations ranging usually from 0.01 to 0.5 mole, preferably from 0.03 to 0.3 mole. It is preferred that the water-soluble aluminum compound is contained so as to amount to from approximately 1% to 10%,
20 preferably from approximately 2% to 5%, as the effective concentrations in the injectable preparations.

As tannic acid to be employed for the curing injectable solution according to the present invention, there may be employed one derived from a variety of
25 plants. The most preferred one is tannic acid derived from gallnut. Tannic acid may be contained at a rate ranging usually from 0.01% to 2.0%, preferably from 0.05% to 1.5%, as the effective concentrations in the injectable preparations. The tannic acid may be added in a concentration
30 beyond the above range by adjusting the amounts of the other components, particularly sodium hydrogen sulfite; however, in this case, care should be paid in preparing and storing the compositions because the resulting compositions are likely to cause coloring or precipitating or
35 depositing during storage for a long period of time. In this sense, such compositions are inconvenient in handling.

This is the replacement sheet

Date: 7 OCT 1996



As described hereinabove, aluminum potassium sulfate may be decomposed to form aluminum ions such as Al^{3+} , $\text{Al}(\text{OH})^{2+}$, $\text{Al}(\text{OH})^+$ and the like upon dissociation in the solution and react with hydroxyl ion, OH^- , to form
5 aluminum hydroxide, $\text{Al}(\text{OH})_3$. If such aluminum ions are present in the solution, tannic acid is reacted directly with them, whereby the solution is likely to cause precipitating.

As the chelating agent to be employed for the
10 present invention, there may be mentioned any compound having the action of trapping minute amounts of metal ions present in the solution. The chelating agent may include, for example, citric acid or a salt thereof such as sodium citrate. The amount of the chelating agent may be in the
15 range of from approximately 10% to 80%, preferably from approximately 20% to 50%, with respect to the amount of the water-soluble aluminum compound, although the amount of the chelating agent may be varied with the kind or the amount of the water-soluble aluminum compound, or the
20 like.

In preparing the compositions for curing the affected abnormal tissues in accordance with the present invention, the chelating agent such as sodium citrate is added to a solution containing the water-soluble aluminum
25 compound before formulating tannic acid with the water-soluble aluminum compound, in order to avoid the direct reaction of the tannic acid with the water-soluble aluminum compound and to cause no precipitating. Once the chelating agent is added to the solution containing the
30 water-soluble aluminum compound, the chelating agent is caused to react with the aluminum ions present in the solution, resulting in the formation of complex aluminum ions and removing the metal ions from the solution to which tannic acid is to be added, the metal ions being
35 reactable with the tannic acid and as a result being likely to cause forming precipitates. To the solution

This is the replacement sheet

Date:

7 OCT 1996



treated in the manner as described hereinabove is added tannic acid to thereby yield a solution in which the tannic acid is not reacted directly with the metal ions, such as aluminum ions, derived from the water-soluble aluminum compound and in which no precipitates are formed. Theoretically, for example, if 0.65 molecule of the aluminum ion is present with respect to one molecule of sodium citrate ion and the former is to be linked to the latter, no free aluminum ion is present in the solution. Practically, however, as the sodium citrate ion exists in a neutral state or in the form of a citric acid dihydrogen ion in the range of such a strong acid as the composition according to the present invention, such amounts are insufficient to trap the aluminum ions in the 1.65-fold concentrations as complex ions. Hence, in this case, it is preferred to select a solution having the composition so as to allow free aluminum ions to exist in a range that does not exceed a solubility product constant of aluminum tannate.

Further, tannic acid is unstable against light or air in a solid state and it is lesser stable in the solution from the point of view of a diffusion velocity between the reactive substances. For the purpose to prevent oxidation of tannic acid, there may be used an antioxidant such as, for example, sodium hydrogen sulfite. The rate of sodium hydrogen sulfite to be used as the antioxidant in accordance with the present invention may be usually from approximately 50% to 200%, preferably from approximately 70% to 150%, with respect to the amount of the tannic acid. If the sodium hydrogen sulfite would be contained in a concentration beyond the above range, the resulting injectable preparations cannot accomplish the desired effects sought to be achieved by the present invention.

In order to make the composition according to the present invention more stable, there may be added as



needed the polyvalent alcohol and/or saccharide, which are or is conventionally employed for curable compositions. As the polyvalent alcohol and/or the saccharide to be employed for the present invention, there may be mentioned
5 glycerin, glucose, fructose, xylitol, mannose, mannitol, galactose, dextran and the like. Particularly, dextran has the action of raising the viscosity of the resulting injectable preparations. The polyvalent alcohol and/or saccharide may be employed singly or in combination of two
10 or more. Further, the amount of the polyvalent alcohol and/or saccharide is not limited to a particular one as long as the polyvalent alcohol and/or saccharide may be contained at such a rate so as to raise the osmosis of the resulting injectable preparations by approximately three
15 times to fifteen times, preferably from approximately four times to eight times, that of physiological saline. In addition, the polyvalent alcohol and/or saccharide are or is preferably contained in the range of from approximately 3% to 20%, preferably from approximately 5% to 15%, as the
20 effective concentration in the injectable preparations.

Further, the compositions according to the present invention may contain another component which hitherto has been conventionally employed as an ingredient for compositions, such as an agent for increasing viscosity of a solution, e.g. dextran or the like, or an anti-septic agent, e.g. phenol, benzyl alcohol, benzalkonium
25 chloride, p-aminobenzoic acid ester or the like. These components may optionally be employed within the range that does not substantially affect the effects of the compositions adversely.
30

In accordance with the present invention, it is of significance in terms of storage of the resulting preparations that the liquid property of the injectable preparations containing the composition is adjusted to be
35 from pH1.0 to pH3.5, preferably from pH2.0 to pH3.0.

When the compositions according to the present

This is the replacement sheet

Date: 7 OCT 1996

invention can be prepared by means of the method according to the present invention, the liquid properties of the compositions may be usually set within the above-defined range without special adjustment and, in this case, it is not particularly required to adjust the liquid properties of the resulting injectable preparations after or before the preparation of the compositions. It is also possible to adjust the liquid properties of the compositions, as needed, to the optimal level with a pharmacologically non-toxic acid or alkali, which are conventionally used for the formulation of the injectable preparations. Such agents may include, for example, a mineral acid such as hydrochloric acid or sulfuric acid, an organic acid such as citric acid, sodium hydrogen carbonate, sodium hydroxide or the like. The preparations having the liquid properties within the range as defined hereinabove can be stored in an extremely stable manner for a long period of time without causing any coloring or depositing or precipitating.

In order to prepare the compositions for curing the affected abnormal tissues according to the present invention from the components as described hereinabove, it is necessary to formulate each of the components in accordance with the order and conditions of formulation, as will be described hereinafter, with the properties of each component taken into consideration.

Specifically, the compositions according to the present invention can be prepared by formulating the sodium hydrogen sulfite, the water-soluble aluminum compound and the chelating agent in an optional order into a formulation and adding tannic acid to the resulting formulation.

In addition, the polyvalent alcohol and/or the saccharide may be added to the formulation or a mixture prepared by adding tannic acid to the formulation.

Alternatively, the compositions for curing the

This is the replacement sheet

Date: 7 OCT 1996

affected abnormal tissues according to the present invention may be prepared by separately forming a formulation by admixing the water-soluble aluminum compound with the chelating agent and a formulation by admixing tannic acid with the sodium hydrogen sulfite and then combining the two formulations together into the compositions.

In this case, too, the polyvalent alcohol and/or the saccharide may be added to either one or both of the formulations prepared in the alternative manner as have been described hereinabove or the mixture obtained by combining the two formulations.

In summary, the methods for the preparation of the compositions for curing the affected abnormal tissues according to the present invention may comprise, as a method, adding tannic acid to the formulation prepared by admixing sodium hydrogen sulfite with all the components other than tannic acid and sodium hydrogen sulfite in an optional way or, as an alternative method, separately preparing the formulation by admixing the water-soluble aluminum compound with the chelating agent and the another formulation by admixing the tannic acid with the sodium hydrogen sulfite and then combining the formulation together with the another formulation into the mixture and, as needed, adding the polyvalent alcohol and/or saccharide to the formulation or formulations or to the mixture at any stage of preparation. By formulating each of the components in the manner as described hereinabove, the oxidation of tannic acid can be prevented as well as the direct reaction of tannic acid with the metal ions such as the aluminum ions derived from the water-soluble aluminum compound can also be prevented, thereby enabling the formation of the stable compositions for curing the affected abnormal tissues according to the present invention in a constant manner.

In the method for the preparation of the compositions for curing the affected abnormal tissues

This is the replacement sheet

Date: - 7 OCT 1996

according to the present invention, the pH range of the compositions can be made, as needed, at any stage of formulation or admixture of the components so as for the resulting injectable preparations to demonstrate the liquid properties within the above-defined level, i.e. from pH1.0 to pH3.5. More specifically, when the compositions are prepared by adding tannic acid to the formulation prepared by admixing all the components other the tannic acid, the liquid properties of the injectable preparations can be adjusted at any or every stage of formulation or admixture by admixing the water-soluble aluminum compound and the chelating agent with sodium hydrogen sulfite and admixing tannic acid to the resulting formulation and adding the polyvalent alcohol and/or saccha-ride to the resulting mixture as needed. Alternatively, when the compositions are prepared by admixing the formulation consisting of the water-soluble aluminum compound and the chelating agent with the formulation consisting of the tannic acid and the sodium hydrogen sulfite, the liquid properties of the injectable preparations can also be adjusted at any or every stage of formulation or admixture to the above-defined level by admixing the resulting formulations together with each other to yield the mixture and adding the polyvalent alcohol and/or saccharide to the resulting mixture as needed.

In the methods for the preparation of the compositions for curing the affected abnormal tissues according to the present invention, it is preferred that any or every component of the composition is formulated with each other under atmosphere of an inert gas. As the inert gases to be used for this purpose, there may preferably be mentioned, for example, nitrogen gases.

Further, it is preferred that the compositions according to the present invention are prepared by formulating each of the components under conditions under

This is the replacement sheet

Date: - 7 OCT 1996

which oxygen does not exist in an atmosphere or in water to be used in no substantial amount or in an amount restricted within the level that does not adversely affect the resulting compositions. Such level may be, for example, 1/1,000 or less with respect to the level in a stationary state.

The compositions thus prepared in the manner as described hereinabove are then filtered and sterilized by means of conventional methods and filled in a container such as colorless hard glass ampoules or glass bottles. They are then sterilized by high-pressure steam, as needed, and stored in a cold place.

In accordance with the method for the preparation of the compositions for curing the affected abnormal tissues, it is preferred that each or every step of the method be carried out in the presence of inert gases such as nitrogen gases. The oxygen dissolved in the injectable preparations are usually removed by conventional methods and the air present in the injectable preparations is replenished with nitrogen gases.

The compositions according to the present invention can be lyophilized by conventional methods. They also can be applied by dissolving the components in distilled water in site. In this case, a solution prepared by dissolving the polyvalent alcohol and/or saccharide may also be used as a solution for use in dissolving the compositions in site.

The compositions for curing the affected abnormal tissues according to the present invention have the peculiar properties of killing the affected abnormal tissues of the digestive organs, particularly the large intestine and rectum, upon contact with the locations of the tissues affected with the piles or hemorrhoids, such as internal piles or hemorrhoids, archoptoma or the like, the uplift affected tissues, the tissues affected with hepatic tumor and the like.

This is the replacement sheet

Date: - 7 OCT 1996



The compositions according to the present invention can demonstrate the strong action of killing the cells of the affected abnormal tissues while holding the states or shapes of the cells. In other words, it is anticipated that the compositions can kill the cells of the affected abnormal tissues upon contact by application and then cause the killed cells to fall off from the normal tissues. By allowing the killed cells to fall off from the normal tissues, the compositions according to the present invention can sclerose the affected abnormal tissues and cure them in mild conditions.

BEST MODE FOR CARRYING OUT THE INVENTION

The compositions for curing the affected abnormal tissues according to the present invention will be described in more detail by way of examples.

5 Example No. 1:

The composition for curing the affected abnormal tissues according to this example contained the following components:

	Aluminum potassium sulfate	400 mg
10	Sodium citrate	150 mg
	Sodium hydrogen sulfite	15 mg
	Tannic acid	15 mg
	Dextran 40	70 mg
	Glycerin	1,000 mg
15	Injectable distilled water	To make 10 ml

The injectable distilled water prepared so as to comply with Pharmacopedia Japonica was treated to remove dissolved oxygen by heating it at 100 °C for five minutes. After the completion of heating, nitrogen gases were introduced into the treated water and allowed to cool to room temperature.

20 Separately, the total amount of dextran 40 was fully dissolved in an appropriate solvent in advance because it is less soluble to the solution for use.

This is the replacement sheet

Date: - 7 OCT 1996

The total amount of sodium hydrogen sulfite was dissolved into an appropriate amount of the injectable distilled water, and the resulting solution was added with the dextran 40 solution and then with sodium citrate, followed by the addition thereto of the total amounts of aluminum potassium sulfate and glycerin. To the resulting solution was added the total amount of tannic acid. The formulation of each of the components was carried out while nitrogen gases had been kept introduced thereinto. The resulting solution was stirred for about 30 minutes and filtered through a filter. Into the filtrate were introduced nitrogen gases to yield the objective composition. The composition had a pH of 2.7.

The resulting solution was then filled in glass vials or ampoules. Before and after filling, the air in the solution was replenished with nitrogen gases and the vials or ampoules were sealed, followed by storage in a cold dark place.

Example No. 2:

The composition having the same components as the one prepared in Example No. 1 was prepared in substantially the same manner as in Example No. 1 with the exception that the dextran 40 solution, sodium citrate, aluminum potassium sulfate and glycerin were added in the order of sodium citrate, aluminum potassium sulfate, glycerin and the dextran 40 solution. The resulting composition had a pH of 2.6.

Example No. 3:

The composition having the same components as the one prepared in Example No. 1 was prepared in substantially the same manner as in Example No. 1 with the exception that the dextran 40 solution, sodium citrate, aluminum potassium sulfate and glycerin were added in the order of aluminum potassium sulfate, glycerin, the dextran 40 solution and sodium citrate. The resulting composition had a pH of 2.7.

This is the replacement sheet

Date: 7 OCT 1996

Example No. 4:

The composition having the same components as the one prepared in Example No. 1 was prepared in substantially the same manner as in Example No. 1 with the exception that the dextran 40 solution, sodium citrate, aluminum potassium sulfate and glycerin were added in the order of glycerin, the dextran 40 solution, sodium citrate and aluminum potassium sulfate. The resulting composition had a pH of 2.7.

Example No. 5:

The composition for curing the affected abnormal tissues according to this example contained the following components:

	Aluminum chloride	400 mg
15	Tannic acid	15 mg
	Sodium citrate	150 mg
	Dextran 40	70 mg
	Sodium hydrogen sulfite	15 mg
	Mannitol	1,500 mg
20	Injectable distilled water	To make 10 ml

The injectable distilled water was treated to remove dissolved oxygen by heating at 100 °C for five minutes. After the completion of heating, nitrogen gases were introduced into the treated water and allowed to cool to room temperature.

The total amount of sodium hydrogen sulfite was dissolved into an appropriate amount of the injectable distilled water thermally treated, and the resulting solution was added with the dextran 40 solution prepared separately and then with sodium citrate, followed the addition thereto of the total amounts of aluminum chloride and mannitol. To the resulting solution was then added the total amount of tannic acid yielding a solution. The formulation of each of the components was carried out while nitrogen gases had been kept introduced thereinto. The resulting solution was stirred for about 30 minutes,

This is the replacement sheet

Date: 7 OCT 1996

added with hydrochloric acid to adjust its pH to pH3.0 and filtered through a filter. Into the filtrate were introduced nitrogen gases to yield the objective composition.

5 The resulting solution was then filled in glass vials or ampoules. Before and after filling, the air in the solution was replenished with nitrogen gases and the vials or ampoules were sealed, followed by storage in a cold dark place.

Example No. 6:

10 The composition of this example contained the components as follows:

Aluminum sulfate	400 mg
Tannic acid	15 mg
Sodium citrate	150 mg
15 Dextran 40	70 mg
Sodium hydrogen sulfite	15 mg
Fructose	2,000 mg
Injectable distilled water	To make 10 ml

20 The injectable preparations were prepared by formulating each of the components in substantially the manner as in Example No. 5 with the exception that aluminum chloride was replaced with aluminum sulfate and mannitol was replaced with fructose. The resulting composition had a pH of 2.7.

25 Example No. 7:

The composition of this example contained the components as follows:

Aluminum carbonate	200 mg
Tannic acid	15 mg
30 Sodium citrate	150 mg
Dextran 40	70 mg
Sodium hydrogen sulfite	15 mg
Xylitol	2,000 mg
Injectable distilled water	To make 10 ml

35 The injectable preparations were prepared in substantially the same manner as in Example No. 5 with the

exception that aluminum chloride was replaced with aluminum carbonate and mannitol was replaced with xylitol. The resulting composition was treated with sulfuric acid to give a pH of 2.7.

5 Example No. 8:

The composition of this example contained the components as follows:

	Aluminum acetate	200 mg
	Tannic acid	15 mg
10	Sodium citrate	150 mg
	Dextran 40	70 mg
	Sodium hydrogen sulfite	15 mg
	Glucose	3,000 mg
	Injectable distilled water	To make 10 ml

15 The injectable preparations were prepared in substantially the same manner as in Example No. 5 with the exception that aluminum chloride was replaced with aluminum acetate and mannitol was replaced with glucose. The resulting composition was treated with sulfuric acid
20 to give a pH of 2.7.

Example No. 9:

The composition for curing the affected abnormal tissues according to this example contained the components as follows:

25	Aluminum potassium sulfate	400 mg
	Tannic acid	15 mg
	Sodium citrate	150 mg
	Dextran 40	70 mg
	Sodium hydrogen sulfite	10 mg
30	Glycerin	1,000 mg
	Injectable distilled water	To make 10 ml

The injectable preparations were prepared by formulating the above components in substantially the same manner as in Example No. 1. The resulting composition was
35 adjusted with sulfuric acid to a pH of 2.7.

Example No. 10:

This is the replacement sheet

Date: - 7 OCT 1996

The composition for curing the affected abnormal tissues according to this example contained the components as follows:

	Aluminum potassium sulfate	400 mg
5	Tannic acid	30 mg
	Sodium citrate	150 mg
	Dextran 40	70 mg
	Sodium hydrogen sulfite	30 mg
	Glycerin	1,000 mg
10	Injectable distilled water	To make 10 ml

The injectable preparations were prepared by formulating the above components in substantially the same manner as in Example No. 1. The resulting composition was adjusted with sulfuric acid to a pH of 2.8.

15 Example No. 11:

The composition for curing the affected abnormal tissues according to this example contained the components as follows:

	Aluminum potassium sulfate	400 mg
20	Tannic acid	50 mg
	Sodium citrate	150 mg
	Dextran 40	70 mg
	Sodium hydrogen sulfite	70 mg
	Glycerin	1,000 mg
25	Injectable distilled water	To make 10 ml

The injectable preparations were prepared by formulating the above components in substantially the same manner as in Example No. 1. The resulting composition was adjusted with sulfuric acid to a pH of 2.7.

30 Example No. 12:

The composition for curing the affected abnormal tissues according to this example contained the components as follows:

	Aluminum potassium sulfate	400 mg
35	Tannic acid	70 mg
	Sodium citrate	150 mg

This is the replacement sheet

Date: - 7 OCT 1996

Dextran 40	70 mg
Sodium hydrogen sulfite	70 mg
Glycerin	1,000 mg
Injectable distilled water	To make 10 ml

5 The injectable preparations were prepared by formulating the above components in substantially the same manner as in Example No. 1. The resulting composition had a pH of 3.2.

Example No. 13:

10 The composition for curing the affected abnormal tissues according to this example contained the components as follows:

Aluminum potassium sulfate	400 mg
Tannic acid	90 mg
15 Sodium citrate	150 mg
Dextran 40	70 mg
Sodium hydrogen sulfite	100 mg
Glycerin	1,000 mg
Injectable distilled water	To make 10 ml

20 The injectable preparations were prepared by formulating the above components in substantially the same manner as in Example No. 1. The resulting composition was adjusted with sulfuric acid to a pH of 2.7.

Example No. 14:

25 The composition for curing the affected abnormal tissues according to this example contained the components as follows:

Aluminum potassium sulfate	400 mg
Tannic acid	100 mg
30 Sodium citrate	150 mg
Dextran 40	70 mg
Sodium hydrogen sulfite	100 mg
Glycerin	1,000 mg
Injectable distilled water	To make 10 ml

35 The injectable preparations were prepared by formulating the above components in substantially the same

manner as in Example No. 1. The resulting composition was adjusted with sulfuric acid to a pH of 2.7.

Example No. 15:

5 The composition for curing the affected abnormal tissues according to this example contained the components as follows:

	Aluminum potassium sulfate	400 mg
	Tannic acid	120 mg
	Sodium citrate	150 mg
10	Sodium hydrogen sulfite	140 mg
	Glycerin	1,200 mg
	Injectable distilled water	To make 10 ml

The injectable preparations were prepared by formulating the above components in substantially the same manner as in Example No. 1. The resulting composition was adjusted with sulfuric acid to a pH of 2.7.

Example No. 16:

20 The composition for curing the affected abnormal tissues according to this example contained the components as follows:

	Aluminum potassium sulfate	400 mg
	Tannic acid	15 mg
	Sodium citrate	300 mg
	Sodium hydrogen sulfite	20 mg
25	Mannitol	3,000 mg
	Injectable distilled water	To make 10 ml

The injectable preparations were prepared in substantially the same manner as in Example No. 1 with the exception that dextran was not used and glycerin was replaced with mannitol. The resulting composition was adjusted with sulfuric acid to a pH of 2.7.

Example No. 17:

35 The composition for curing the affected abnormal tissues according to this example contained the components as follows:

	Aluminum potassium sulfate	400 mg
--	----------------------------	--------

This is the replacement sheet

Date: 7 OCT 1996

Sodium citrate	50 mg
Sodium hydrogen sulfite	15 mg
Tannic acid	15 mg
Glycerin	1,100 mg
Injectable distilled water	To make 10 ml

5

The injectable distilled water prepared so as to comply with Pharmacopedia Japonica was treated to remove dissolved oxygen by heating at 100 °C for five minutes. After the completion of heating, nitrogen gases were introduced into the treated water and allowed to cool to room temperature.

10

The total amount of sodium hydrogen sulfite was dissolved into an appropriate amount of the injectable distilled water, and the resulting solution was added with sodium citrate, followed by the addition thereto of the total amounts of aluminum potassium sulfate and glycerin. To the resulting solution was added the total amount of tannic acid. The formulation of each of the components was carried out while nitrogen gases had been kept introduced thereinto. The resulting solution was stirred for about 30 minutes, adjusted with sulfuric acid to demonstrate a pH of 3.1, and filtered through a filter. Into the filtrate were introduced nitrogen gases to yield the objective composition.

20

The resulting solution was then filled in glass vials or ampoules. Before and after filling, the air in the solution was replenished with nitrogen gases and the vials or ampoules were sealed, followed by storage in a cold dark place.

25

Example No. 18:

30

The composition for curing the affected abnormal tissues according to this example contained the components as follows:

Aluminum potassium sulfate	400 mg
Sodium citrate	100 mg
Sodium hydrogen sulfite	15 mg

35

This is the replacement sheet

Date: 7 OCT 1996

Tannic acid	15 mg
Dextran 40	100 mg
Injectable distilled water	To make 10 ml

5 The injectable distilled water prepared so as to comply with Pharmacopedia Japonica was treated to remove dissolved oxygen by heating at 100 °C for five minutes. After the completion of heating, nitrogen gases were introduced into the treated water and allowed to cool to room temperature.

10 The total amount of sodium hydrogen sulfite was dissolved into an appropriate amount of the injectable distilled water, and the resulting solution was added with the total amounts of the dextran 40 solution separately prepared and sodium citrate, followed by the addition
15 thereto of the total amount of aluminum potassium sulfate. To the resulting solution was added the total amount of tannic acid. The formulation of each of the components was carried out while nitrogen gases had been kept introduced thereinto. The resulting solution was stirred for about
20 30 minutes, adjusted with sulfuric acid to give a pH of 2.8, and filtered through a filter. Into the filtrate were introduced nitrogen gases to yield the objective composition.

25 The resulting solution was then filled in glass vials or ampoules. Before and after filling, the air in the solution was replenished with nitrogen gases and the vials or ampoules were sealed, followed by storage in a cold dark place.

Example No. 19:

30 This example provided the injectable preparations for curing the affected abnormal tissues for use in site, which contained the components as follows:

Agent I:

35	Tannic acid	15 mg
	Sodium hydrogen sulfite	15 mg
	Injectable distilled water	To make 10 ml

This is the replacement sheet

Date: - 7 OCT 1996

Agent II:

Aluminum potassium sulfate	400 mg
Sodium citrate	150 mg
Dextran 40	70 mg
Glycerin	1,000 mg
Injectable distilled water	To make 10 ml

The above Agent I was prepared by adding the total amount of tannic acid in the presence of nitrogen gases to a solution prepared by dissolving sodium hydrogen sulfite in the injectable distilled water. On the other hand, the above agent II was prepared by dissolving sodium citrate in the injectable distilled water in the presence of nitrogen gases and adding thereto aluminum potassium sulfate in the presence of nitrogen gases, followed by addition thereto of dextran and glycerin. The Agents I and II prepared in the above manner were combined into injectable preparations for use in site by adding the Agent II to the Agent I. The injectable preparations were adjusted with sulfuric acid to a pH of 2.7.

Example No. 20:

This example provided the injectable preparations for curing the affected abnormal tissues for use in site which contained the components as follows:

Agent I:

Aluminum potassium sulfate	400 mg
Sodium citrate	150 mg
Sodium hydrogen sulfite	20 mg
Injectable distilled water	To make 10 ml

Agent II:

Tannic acid	20 mg
Glycerin	1,200 mg
Injectable distilled water	To make 10 ml

The above Agent I was prepared by adding the total amounts of sodium hydrogen sulfite and sodium citrate in the presence of nitrogen gases to the injectable distilled water and then aluminum potassium

This is the replacement sheet

Date: - 7 OCT 1996

sulfate to the resulting solution in the presence of nitrogen gases. Separately, the above agent II was prepared by dissolving glycerin and tannic acid in this order in the injectable distilled water in the presence of nitrogen gases. The Agents I and II prepared in the manner as described hereinabove were combined in site for use as injectable preparations by adding the Agent II to the Agent I. The injectable preparations were adjusted with sulfuric acid, as needed, to a pH of 2.7.

10 Example No. 21:

This example provided the injectable preparations for curing the affected abnormal tissues for use in site which contained the components as follows:

Agent I:

15	Aluminum potassium sulfate	400 mg
	Sodium citrate	150 mg
	Injectable distilled water	To make 10 ml

Agent II:

	Tannic acid	50 mg
20	Sodium hydrogen sulfite	100 mg
	Injectable distilled water	To make 10 ml

The above Agent I was prepared by adding the total amount of sodium citrate to the injectable distilled water and then aluminum potassium sulfate to the resulting solution in the presence of nitrogen gases. On the other hand, the above agent II was prepared by dissolving sodium hydrogen sulfite and tannic acid in the injectable distilled water in the presence of nitrogen gases. The above Agent III was prepared in substantially the same manner as above by dissolving sodium hydrogen sulfite in the presence of nitrogen gases in the injectable distilled water. The Agents I and II prepared in the above manner were used as injectable preparations by adding the Agent II to the Agent I. The injectable preparations were adjusted to a pH of 2.7.

35 Example No. 22:

This is the replacement sheet

Date:

= 7 OCT 1996

This example provided the injectable preparations for curing the affected abnormal tissues for use in site which contained the components as follows:

Agent I:

5	Aluminum potassium sulfate	400 mg
	Sodium citrate	150 mg
	Tannic acid	15 mg
	Sodium hydrogen sulfite	15 mg
	Injectable distilled water	To make 10 ml

10 Agent II:

	Glycerin	1,000 mg
	Dextran	70 mg
	Injectable distilled water	To make 10 ml

The above Agent I was prepared by adding the total amount of sodium citrate to the injectable distilled water and then aluminum potassium sulfate to the resulting solution in the presence of nitrogen gases. To the resulting solution was added a solution prepared by dissolving the total amounts of sodium hydrogen sulfite and tannic acid in the injectable distilled water in the presence of nitrogen gases. The resulting Agent I had a pH of 2.7 and was lyophilized in conventional manner, followed by storage for one month in a cold dark place.

The injectable preparations were prepared for use in site by adding the Agent II to the Agent I and used for tests for stability of the preparations in a way as will be described hereinafter.

Comparative Example No. 1:

The composition prepared in Example No. 1 was adjusted with sodium hydroxide to pH4.7 for comparative purposes.

Comparative Example No. 2:

The composition was prepared by adding dextran, aluminum potassium sulfate, glycerin and tannic acid in this consecutive order in the injectable distilled water in the presence of nitrogen gases. The resulting inject-

able preparations were adjusted with sulfuric acid to pH2.7.

Comparative Example No. 3:

5 The injectable preparations of this comparative example was prepared which contained the following components:

Aluminum potassium sulfate	4.0 g
Tannic acid	0.15 g
Sodium citrate	1.5 g
10 Dextran	10 ml
Trichlorobutanol	0.5 g
Glycerin	10 ml
Injectable distilled water	To make 100 ml

15 The injectable preparations were prepared by adding each of the above components to the injectable distilled water in the manner as enumerated hereinabove and the resulting preparations were adjusted with sodium hydroxide to pH4.7.

Comparative Example No. 4:

20 The sclerosing agent having the same composition as disclosed in Japanese Patent Unexamined Publication (Kokai) No. 4-225,920 as the Comparative Preparation Formulation Example No. 1 was prepared in substantially the same manner as disclosed in this publication. More
25 specifically, the composition having the same components was formulated in the same order and in substantially the same manner as disclosed in this publication to give injectable preparations which were then adjusted with sodium hydroxide to pH4-5. The resulting injectable
30 preparations were filled by a 10 ml portion in each of colorless hard glass ampoules which in turn were treated in order to replenish the air in the ampoules with nitrogen gases and then sterilized with high pressure steam in conventional manner.

35 Comparative Example No. 5:

The sclerosing agent having the same composition

as disclosed in Japanese Patent Unexamined Publication (Kokai) No. 4-225,920 as the Comparative Preparation Formulation Example No. 2 was prepared in substantially the same manner as disclosed in this publication. More specifically, the composition having the same components was formulated in substantially the same manner as disclosed in this publication to yield injectable preparations which were then adjusted with sodium hydroxide to pH4-5. The resulting injectable preparations were filled by a 10 ml portion in each of colorless hard glass ampoules which in turn were treated in order to replenish the air in the ampoules with nitrogen gases and then sterilized with high pressure steam in conventional manner.

15 Comparative Example No. 6:

The sclerosing agent having the same composition as disclosed in Japanese Patent Unexamined Publication (Kokai) No. 4-225,920 as the Comparative Preparation Formulation Example No. 5 was prepared in substantially the same manner as disclosed in the publication. More specifically, the composition having the same components was formulated in the same order and in substantially the same manner as disclosed in the publication to give the composition which was then adjusted with sulfuric acid to pH2.7. The resulting aqueous solution was filled by a 50 ml portion in each of colorless hard glass vials which in turn were treated in order to replenish the gases in the vials with nitrogen gases and then sterilized with high pressure steam in conventional manner.

30 Comparative Example No. 7:

Into a test tube were poured simultaneously the same components in the same amounts as Example No. 1, and injectable distilled water was added with stirring to the mixture to make the total amount 10 ml. The resulting solution became turbid in white color and caused precipitating as the time passed by.

This is the replacement sheet

Date: 7 OCT 1996

Comparative Example No. 8:

The same amounts of the same components as indicated in Example No. 1 above were dissolved with stirring in the same order in injectable distilled water. The resulting solution became turbid in white color and caused precipitating as the time has elapsed.

Comparative Example No. 9:

The same amounts of the same components as indicated in Example No. 1 above were dissolved with stirring in the same order in injectable distilled water. The resulting solution became turbid in white color and caused precipitating as the time has passed by.

Comparative Example No. 10:

For the preparation of the composition having the same components and containing the same amounts, respectively, as Example No. 1 above, dextran and glycerin were admixed with injectable distilled water, followed by the addition of aluminum potassium sulfate and tannic acid to the resulting mixture. To the resulting solution were added sodium citrate and sodium hydrogen sulfite to give injectable preparations. It was found that this solution turned turbid in white color at the time when tannic acid was added and it soon caused precipitates in a dark brown color.

Comparative Example No. 11:

A solution (Agent I) was prepared by dissolving 400 mg of aluminum potassium sulfate and 400 mg of tannic acid in 10 ml of injectable distilled water in the presence of nitrogen gases. Separately, a solution (Agent II) was prepared by dissolving 70 mg of dextran, 1,000 mg of glycerin, 15 mg of sodium citrate and 15 mg of sodium hydrogen sulfite in this order in 10 ml of injectable distilled water in the presence of nitrogen gases. The injectable preparations were prepared by admixing Agent I with Agent II. The injectable preparations were found to turn turbid in pale brown color at the time when tannic

This is the replacement sheet

Date: 7 OCT 1956

acid was added to aluminum potassium sulfate in the Agent I and the resulting solution caused precipitates in dark brown color within short.

5 The injectable preparations prepared in the manner as described hereinabove were subjected to tests for stability of preparations.

Tests for Stability of Preparations:

10 After the injectable preparations prepared in the above-mentioned Examples were adjusted to give the pH ranges as defined hereinabove, five colorless hard glass vials were aseptically filled with 10 ml of each of the compositions and the air in the vials was replenished with nitrogen gas under vacuum conditions. The vials were then exposed to white light with 1,000 lux at 40° C and visual
15 observations were made as to coloring and the extent of depositing. Before carrying out the tests for stability of injectable preparations, each of the compositions was found colorless or transparent, yellowish and slightly viscous. The test results are shown in Table 1 below.

20

This is the replacement sheet

Date: - 7 OCT 1996

TABLE 1: Tests for Stability of Preparations

Prepara- tions Example Nos.	Storage Period of Time (Months)					
	0	1	2	3	6	12
1	Colorless or faintly yellowish	Colorless or faintly yellowish	Colorless or faintly yellowish	Colorless or faintly yellowish	Colorless or faintly yellowish	Colorless or faintly yellowish
5	-do-	-do-	-do-	-do-	-do-	-do-
6	-do-	-do-	-do-	-do-	-do-	-do-
7	-do-	-do-	-do-	-do-	-do-	-do-
8	-do-	-do-	-do-	-do-	-do-	-do-
9	Pale yellow	Pale yellow	Pale yellow	Pale yellow	Pale yellow	Pale yellow
10	-do-	-do-	-do-	-do-	-do-	-do-
11	-do-	-do-	-do-	-do-	-do-	-do-
12	-do-	-do-	-do-	-do-	-do-	-do-
13	-do-	-do-	-do-	-do-	-do-	-do-
14	-do-	-do-	-do-	-do-	-do-	-do-
15	-do-	-do-	-do-	-do-	-do-	-do-
16	-do-	-do-	-do-	-do-	-do-	-do-
17	-do-	-do-	-do-	-do-	-do-	-do-

5

10

15

20

This is the replacement sheet

Date: 7 OCT 1996

18	-do-	-do-	-do-	-do-	-do-	-do-
19	-do-	-do-	-do-	-do-	-do-	-do-
20	-do-	-do-	-do-	-do-	-do-	-do-
21	-do-	-do-	-do-	-do-	-do-	-do-
22	-do-	-do-	-do-	-do-	-do-	-do-
Compara- tive Example 1	Colorless or faintly yellowish	White deposit	White deposit	White deposit	White deposit	White deposit
Compara- tive Example 2	-do-	Colored deposit	Colored deposit	Colored deposit	Colored deposit	Colored deposit
Compara- tive Example 3	-do-	White deposit	White deposit	Colored deposit	Colored deposit	Colored deposit
Compara- tive Example 4	-do-	Colored deposit	Colored deposit	Colored deposit	-do-	-do-
Compara- tive Example 5	-do-	-do-	-do-	-do-	-do-	-do-

5

10

15

20

25

This is the replacement sheet

Date:

• 7 OCT 1996

Compara- tive Example 6	-do-	-do-	-do-	-do-	-do-	-do-
Compara- tive Example 7	-do-	-do-	-do-	-do-	-do-	-do-
Compara- tive Example 8	-do-	-do-	-do-	-do-	-do-	-do-
Compara- tive Example 9	-do-	-do-	-do-	-do-	-do-	-do-
Compara- tive Example 10	-do-	-do-	-do-	-do-	-do-	-do-
Compara- tive Example 11	Pale brown	-do-	-do-	-do-	-do-	-do-

5

10

15

20

25

This is the replacement sheet

Date: - 7 OCT 1996

Table 2 below shows the results of the tests for stability of the injectable preparations in substantially the same manner as in Table 1 above with the exception that the temperature for storage was set to 60°C.

5

This is the replacement sheet

Date: 7 OCT 1996

TABLE 2: Tests for Stability of Preparations

Prepara- tions Example Nos.	Storage Period of Time (Months)					
	0	1	2	3	6	12
1	Colorless or faintly yellowish	Colorless or faintly yellowish	Colorless or faintly yellowish	Colorless or faintly yellowish	Colorless or faintly yellowish	Colorless or faintly yellowish
2	-do-	-do-	-do-	-do-	-do-	-do-
3	-do-	-do-	-do-	-do-	-do-	-do-
4	-do-	-do-	-do-	-do-	-do-	-do-
8	-do-	-do-	-do-	-do-	-do-	-do-
9	Pale yellow	Pale yellow	Pale yellow	Pale yellow	Pale yellow	Pale yellow
10	-do-	-do-	-do-	-do-	-do-	-do-
11	-do-	-do-	-do-	-do-	-do-	-do-
12	-do-	-do-	-do-	-do-	-do-	-do-

5

10

15

This is the replacement sheet

Date: 7 OCT 1996

A description will made of experiments for the cytotoxic action of the compositions for curing the affected abnormal tissues according to the present invention.

5 For the injectable preparations obtained in Example No. 1, a comparative review of the cytotoxic effects was made using the endothelial cells of the venous vessel of the human funiculus (primary culture), the fibroblast of the human normal diploid (primary culture)
10 and the rat muscle blast cells (cell culture). As comparative chemicals, there were employed Paoscle™ (containing phenol as a major active ingredient) as an agent for sclerosing the internal piles and Oldamin™ (containing monoethanolamine oleate as a major active ingredient),
15 Aethoxysklerol™ (containing polidocanol as a major active ingredient) and ethanol (containing ethanol as a major active ingredient) as agents for sclerosing esophageal varix.

20 The method for determining the death of the cells was based on the trypan blue dyeing method.

Experiment No. 1:

The method for experiment was as follows.

Each kind of the cells was inoculated at the rate of 5×10^3 cells per dish. A 1:1 mixture of 2%
25 procaine hydrochloride and a test agent which was diluted to a 100-fold or 1,000-fold dilution with a cell culture solution (a 0.5% sodium chloride solution) was prepared. To the inoculant was added the dilution, and the resulting mixture was supplied with a 1:1 mixture of DMEM and HAM
30 F12 and a 10% fetal bovine serum. The test cells were then cultured in 5% CO₂ at 37°C.

35 The resulting culture liquid was digested with trypsin to give a cells floating solution to which an equal amount of the test agent was added. This mixture was allowed to stand for 10 minutes at 37°C and the equal volume of a 0.3% trypan blue solution was added thereto.

This is the replacement sheet

Date: - 7 OCT 1996

The number of the living cells (not dyed with trypan blue) and the dead cells (dyed with trypan blue) were counted in 15 minutes after addition of the trypan blue solution.

As a control, there was used a 0.9% sodium chloride solution (a solution obtained by adding 5% fetal bovine serum to the cells floating solution used for test).

The test results are shown in Table 3 below.

TABLE 3: RATES OF LIVING CELLS

TEST AGENTS	RATES OF LIVING CELLS (%)		
	CELL 1	CELL 2	CELL 3
COMPOSITION OF THE PRESENT INVENTION	96.8	90.3	95.0
PAOSCLE™	79.8	89.3	87.0
OLDAMIN™	0.0	0.0	0.0
AETHOXYSKLEROL™	0.0	0.0	0.0
ETHANOL	0.0	0.0	0.0
CONTROL (0.9% SODIUM CHLORIDE SOLUTION)	97.0	91.7	94.0

NOTES: CELL 1: Endothelial cells of the venous vessel of the human funiculus (primary culture)

CELL 2: Fibroblast of the human normal diploid (primary culture)

CELL 3: Rat muscle blast cells (cell culture)

As is apparent from the test results as shown in Table 3 above, the 0.9% sodium chloride solution used as the control and Paoscle™ did not cause killing a majority of the cells tested, while Oldamin™, Aethoxysklerol™ and ethanol used as the agent for sclerosing the esophageal varix caused the entire number (100%) of the cells.

Among the living cells used in the above tests,

This is the replacement sheet

Date:

- 7 OCT 1996

the fibroblast of the human normal diploid was cultured again. More specifically, the living cells were washed and inoculated in a culture medium solution containing the same culture medium as used before, followed by the culture at 37°C for 24 hours. As a result, it was found that no living cells were counted at all out of the cells exposed to the composition according to the present invention, on the one hand, and that 95% of the cells were found alive and kept growing out of the cells treated with the 0.9% sodium chloride solution and 80% of the cells were alive and kept growing out of the cells treated with Paoscle™, on the other hand.

Experiment No. 2:

The experiment was carried out in substantially the same manner as in Experiment No. 1 above, with the exception that a 2% xylocaine hydrochloride solution was used for the 1:1 mixture of the test agent added to the liquid cell culture medium in place of the 2% procaine hydrochloride solution. It was found as a result of re-culture that the total number (100%) of the fibroblast of the human normal diploid cultured again were dead.

Experiment No. 3:

The experiment was carried out in substantially the same manner as in Experiment No. 1 above, with the exception that the test chemical alone was added to the cell culture medium (0.9% sodium chloride solution + 5% fetal bovine serum). It was found as a result of re-culture that the total number (100%) of the fibroblast of the human normal diploid cultured again were dead.

Experiment No. 4:

The experiment was carried out in substantially the same manner as in each of the experiment Nos. 1, 2 and 3 above, with the exception that the re-culture was conducted in a liquid cell culture medium to which no 5% fetal bovine serum was not added. It was found as a result of re-culture that the total number (100%) of the fibro-

blast of the human normal diploid exposed to the composition according to the present invention were dead, while it was found that no cells were killed by the liquid cell culture medium (0.9% sodium chloride solution) used as the control.

INDUSTRIAL UTILIZATION OF THE INVENTION

The compositions according to the present invention are constant and stable in formulation as well as effective for curing the affected abnormal tissues of the digestive system, particularly the large intestine and rectum, because the compositions comprising substantially the water-soluble aluminum compound, the chelating agent, tannic acid and sodium hydrogen sulfite are adjusted within a pH range of from pH1.0 to pH3.5 in such a manner that tannic acid does not react with the metal ions, such as aluminum ions, derived from the water-soluble aluminum compound and no formation of precipitates are caused.

Further, the compositions for curing the affected abnormal tissues according to the present invention can be made more stable in formulation by adding the polyvalent alcohol and/or saccharide, as needed, to the compositions substantially comprising the water-soluble aluminum compound, the chelating agent, tannic acid and sodium hydrogen sulfite.

In addition, in preparing the compositions for curing the affected abnormal tissues according to the present invention, tannic acid is prevented from causing precipitating as a result of its reaction with the metal ions, such as aluminum ions, decomposed from the water-soluble aluminum compound, by adding it to a formulation consisting substantially of the water-soluble aluminum compound, the chelating agent and sodium hydrogen sulfite, whereby the stable compositions having the constant formulation can be prepared.

Furthermore, it is noted that the admixture of

This is the replacement sheet

Date: - 7 OCT 1996

a first formulation comprising the water-soluble aluminum compound and the chelating agent with a second formulation comprising tannic acid and sodium hydrogen sulfite can lead to the preparation of the compositions according to the present invention, which can offer the advantages in preparing the compositions for curing the affected abnormal tissues according to the present invention that the reaction of tannic acid with the metal ions such as aluminum ions decomposed from the water-soluble aluminum compound can be controlled more readily so as to cause no precipitating.

It is further advantageous that the optional addition of the polyvalent alcohol and/or saccharide to the compositions consisting substantially of the water-soluble aluminum compound, the chelating agent, tannic acid and sodium hydrogen sulfite can contribute greatly to making the compositions more stable and preparing the compositions in a ready way because the timing of the addition can be chosen in an optional way.

Furthermore, in preparing the compositions according to the method according to the present invention, it is extremely advantageous to enable the pH range of the compositions for curing the affected abnormal tissues to be adjusted at an appropriate stage of formulation of each of the components, particularly in terms of making it easy to prevent tannic acid from being oxidized and making it to prevent tannic acid from being reacted with the metal ions derived from the water-soluble aluminum compound.

The present invention can offer the further advantage that the compositions according to the present invention can be made stable in formulation by formulating each of the components at an appropriate stage under atmosphere of inert gases.

Likewise, it is beneficial in preparing the stable compositions for curing the affected abnormal

This is the replacement sheet

Date:

- 7 OCT 1996

tissues according to the present invention having the constant and stable formulation that each of the components is formulated under the condition under which no substantial amount or an extremely limited amount of oxygen exists in an atmosphere or in a liquid state because the such condition can contribute particularly to a prevention of tannic acid from being oxidized.

In addition, it is very beneficial in preparing the stable compositions for curing the affected abnormal tissues according to the present invention having the constant formulation that a solution containing the polyvalent alcohol and/or saccharide can be added to or mixed with the first formulation comprising the water-soluble aluminum compound and the chelating agent and/or the second formulation comprising tannic acid and sodium hydrogen sulfite or a mixture of the first formulation with the second formulation immediately before administration, because this way of preparing the injectable preparations can prevent each of the components from being changed or transformed according to a lapse of time.

The compositions according to the present invention can offer the further advantage that the injectable preparations can be stored in a stable state for a long period of time because it is possible to adjust the pH range of the compositions after all the components have been formulated. In addition, it is beneficial for stabilizing the compositions for a long period of time that the compositions can be stored under atmosphere of inert gases.



C L A I M S

1. A composition for curing affected abnormal tissues characterized in that said composition comprises substantially a water-soluble aluminum compound, tannic acid, sodium hydrogen sulfite and a chelating agent and that a pH range of said composition is adjusted to from pH1.0 to pH3.5.

2. A composition for curing affected abnormal tissues as claimed in claim 1, further comprising containing a polyvalent alcohol and/or a saccharide.

3. A composition for curing affected abnormal tissues as claimed in claim 1 or 2, wherein said water-soluble aluminum compound is selected from aluminum chloride, aluminum sulfate, aluminum carbonate, aluminum acetate, aluminum nitrate, aluminum lactate, aluminum tartrate, aluminum salicylate, aluminum sodium sulfate, aluminum potassium sulfate, aluminum cesium sulfate and aluminum ammonium sulfate.

4. A composition for curing affected abnormal tissues as claimed in claim 1, 2 or 3, wherein said water-soluble aluminum compound is contained at a rate of from 1% to 10% as an effective concentration in preparations.

5. A composition for curing affected abnormal tissues as claimed in any one of claims 1 to 4, wherein said tannic acid is contained at a rate of from 0.01% to 2.0% as an effective concentration in preparations.

6. A composition for curing affected abnormal tissues as claimed in any one of claims 1 to 5, wherein said chelating agent is citric acid or a salt thereof.

7. A composition for curing affected abnormal tissues as claimed in claim 6, wherein said chelating agent is contained at a rate of from 10% to 80% with respect to the amount of said water-soluble aluminum compound.

8. A composition for curing affected abnormal

This is the replacement sheet



Date: - 7 OCT 1996



tissues as claimed in any one of claims 1 to 7, wherein said sodium hydrogen sulfite is contained at a rate of from 50% to 200% with respect to the amount of said tannic acid.

5 9. A composition for curing affected abnormal tissues as claimed in claim 8, wherein said sodium hydrogen sulfite is contained at a rate of from 70% to 150% with respect to the amount of said tannic acid.

10 10. A composition for curing affected abnormal tissues as claimed in claim 2, wherein said polyvalent alcohol and/or said saccharide is selected from mannitol, fructose, xylitol, glucose, galactose, mannose, lactose and glycerin.

15 11. A composition for curing affected abnormal tissues as claimed in claim 10, wherein said polyvalent alcohol and/or said saccharide are or is contained at a rate of from 3% to 20% as an effective concentration in preparations.

20 12. A composition for curing affected abnormal tissues as claimed in any one of claims 1 to 11, wherein said pH range is set to be from pH2.0 to pH3.0.

25 13. A method for the preparation of a composition for curing affected abnormal tissues comprising substantially a water-soluble aluminum compound, a chelating agent, tannic acid and sodium hydrogen sulfite and having a pH of said composition set to range from pH1.0 to pH3.5, characterized in that tannic acid is added to a mixture prepared by formulating said water-soluble aluminum compound, said chelating agent and said sodium
30 hydrogen sulfite in an optional order.

35 14. A method for the preparation of a composition for curing affected abnormal tissues as claimed in claim 13, wherein a polyvalent alcohol and/or a saccharide is added to said mixture prepared by formulating said sodium hydrogen sulfite, said water-soluble aluminum compound and/or said chelating agent.





15. A method for the preparation of a composition for curing affected abnormal tissues as claimed in claim 13 or 14, wherein a pH range of said mixture to which said tannic acid is added is adjusted to said pH range, as needed.

16. A method for the preparation of a composition for curing affected abnormal tissues characterized in that a first formulation is prepared by mixing a water-soluble aluminum compound with a chelating agent, a second formulation is separately prepared by mixing tannic acid with sodium hydrogen sulfite, and said first formulation is admixed with said second formulation to yield said composition.

17. A method for the preparation of a composition for curing affected abnormal tissues as claimed in claim 16, wherein a polyvalent alcohol and/or a saccharide are or is added to each of said first formulation and said second formulation or either one of said first formulation and said second formulation or to a mixture of said first formulation with said second formulation.

18. A method for the preparation of a composition for curing affected abnormal tissues as claimed in claim 16 or 17, wherein a pH range of each of said first and second formulations or either one of said first and second formulation or a mixture of the first and second formulations is adjusted, as needed, to said pH range.

19. A method for the preparation of a composition for curing affected abnormal tissues as claimed in any one of claims 13 to 18, wherein each of components constituting said composition or either of said components is formulated with each other under inert atmosphere.

20. A method for the preparation of a composition for curing affected abnormal tissues as claimed in any one of claims 13 to 19, wherein oxygen exists in atmosphere or in water to be used in no substantial amount or at such a restricted amount as failing to adversely





affect said composition.

21. A method for the preparation of a composition for curing affected abnormal tissues as claimed in any one of claims 13 to 20, wherein a pH of said composition is adjusted as needed to said pH range after all of said components constituting said composition have been formulated.

22. A method for the preparation of a composition for curing affected abnormal tissues as claimed in any one of claims 13 to 21, wherein said composition is filled under inert atmosphere in a container for injection or a container for storing injectable preparations.

23. Use of a composition for curing affected abnormal tissues comprising substantially a water-soluble aluminum compound, a chelating agent, tannic acid and sodium hydrogen sulfite and having a polyvalent alcohol and/or saccharide added as needed to said composition as well as having a pH range of said composition adjusted to from pH1.0 to pH3.5, characterized in that said composition is applied to kill cells of the affected abnormal tissues to thereby cure diseases caused by the affected abnormal tissues.

24. Use of a composition for curing affected abnormal tissues as claimed in claim 23, wherein said composition is applied to cure piles or hemorrhoids, uplift affected tissues of the digestive system or hepatic tumor.

25. Use of a composition for curing affected abnormal tissues as claimed in claim 23 or 24, wherein said composition is applied in the form of an injection.



This is the replacement sheet

Date: - 7 OCT 1996

COMPOSITIONS FOR CURING AFFECTED ABNORMAL
TISSUES, METHOD FOR THE PREPARATION THEREOF, AND
USAGE THEREOF

A B S T R A C T

Injectable preparations of the composition for curing affected abnormal tissues are prepared by formulating sodium hydrogen sulfite with all the other components except tannic acid to yield a first mixture and adding tannic acid to the first mixture or by formulating a water-soluble aluminum compound and a chelating agent to yield a first formulation, formulating tannic acid and sodium hydrogen sulfite to yield a second formulation and admixing the first formulation with the second formulation to yield a second mixture and, as needed, adding a polyvalent alcohol and/or a saccharide to the first and/or second formulations or to the first or second mixture. This preparation can prevent tannic from being oxidized and from reacting directly with an aluminum ion derived from sodium hydrogen sulfite, whereby the composition having a stable formulation can be provided.

The resulting compositions for curing the affected abnormal tissues is stable in quality and constant in formulation.

2-2200000

This is the replacement sheet

Date: 7 OCT 1996

flavonoid, a catechin or a polycarboxylic acid. As this composition contains the extract of the medicinal plant as the stabilizing agent, however, it suffers from the disadvantages in terms of formulating preparations that it is extremely difficult to provide injectable preparations with a constant formulation and stable quality as well as that there is still the possibility that the stabilizing agent may be contaminated with minutes amounts of unidentified substances even if it would be extracted and purified elaborately through plural steps. It has further been found that such a composition comprising tannic acid and aluminum potassium sulfate may cause coloring or, in some cases, precipitating, even if it contains the extract of the plant as a stabilizing agent, when stored for a long period of time in a liquid state. This also may cause the problem when it is applied as an injectable agent.

In addition, PCT International Publication No. WO94/06443 (International Publication Date: March 31, 1994) discloses a composition for curing affected abnormal tissues of the digestive system as injectable preparations, which comprises a composition containing a water-soluble aluminum compound in a concentration ranging from 0.01 mole/litre to 0.5 mole/litre, tannic acid in an amount of 0.5% w/v to 25.0% w/v with respect to the amount of the water-soluble aluminum compound, sodium hydrogen sulfite, and a polyvalent alcohol or a saccharide; in which a pH of said composition is adjusted so as to become in the range of from pH1.5 to pH3.5. The components of the compositions disclosed in this publication are the same as those of the ones to which the present invention is directed. This publication, however, discloses a method for the preparation of the composition for curing the affected abnormal tissues of the digestive system as well as the compositions consisting of the same components as those of the present invention. The published method comprises formu-

REPLACEMENT SHEETS		SG
☒	Description : paged 41 to paged 44	
☒	Claim(s) : paged 44 to paged 44	
☐	Drawing(s) : paged to paged	
☐	Abstract : paged to paged	
DATE OF RECEIPT 01/2/99		

This is the replacement sheet

Date: 11 FEB 1999

a constant and stable manner without causing any precipitates simply by formulating all the components in a simultaneous or random way.

As the result of a detailed review on the order and conditions of formulating the components in preparing the preparations for injection, it has been found by the present inventor that the injectable preparations for curing the affected abnormal tissues having a constant and stable composition can be prepared by arranging the order of formulation of its components and the concentrations thereof. Thus, the present invention has been completed from this finding.

DISCLOSURE OF INVENTION

In one aspect, the present invention is directed to an injectable composition for treating hemorrhoidal tissues said composition including a water-soluble aluminum compound, tannic acid, an antioxidant and a chelating agent; said water-soluble aluminum compound being in a concentration of from 0.01 mol/litre to 0.5 mole/litre of said composition; said water-soluble aluminum compound being contained in an amount of from 1% w/v to 10% w/v of said composition; said tannic acid being contained in an amount of from 0.01% w/v to 2.0% w/v; said chelating agent being contained in an amount of from 10% w/w to 80% w/w with respect of said water-soluble aluminum compound; said antioxidant being contained in an amount of 50% w/w to 200% w/w with respect to said tannic acid; and a pH range of said composition being from pH1.0 to pH3.5; wherein said composition is prepared by:

admixing said water-soluble aluminum compound and said chelating agent or a mixture of said water-soluble aluminum compound with said chelating agent with said tannic acid and said antioxidant or with a mixture of said tannic acid and said antioxidant.

Throughout the specification, the phrase "hemorrhoidal tissue" includes piles and hemorrhoid tissues, affected uplift tissues of the digestive tracts, hepatic tumor, and the like.

In another aspect, the present invention is directed to a method for preparing an injectable composition for treating hemorrhoidal tissues according to the first aspect of the invention comprising the steps of:

admixing said water-soluble aluminum compound with said chelating agent to form a first mixture; and

This is the replacement sheet

Date: 11 FEB 1999

admixing said first mixture with said tannic acid and said antioxidant or with a mixture of said tannic acid and said antioxidant.

In another aspect, the present invention is directed to a method for preparing an injectable composition for treating hemorrhoidal tissues according to the first aspect of the invention comprising the steps of:

admixing said tannic acid with said antioxidant to form a first mixture; and

admixing said first mixture with said water-soluble aluminum compound with said chelating agent or with a mixture of said water-soluble aluminum compound with said chelating agent.

In another aspect, the present invention is directed to a method for preparing an injectable composition for treating hemorrhoidal tissues according to the first aspect of the invention comprising the steps of:

admixing said water-soluble aluminum compound, said chelating agent and said antioxidant in an optional order to form a first mixture; and admixing said first mixture with said tannic acid.

In another aspect, the present invention is directed to a method for preparing an injectable composition for treating hemorrhoidal tissues according to the first aspect of the invention comprising the steps of:

admixing said tannic acid, said chelating agent and said antioxidant in an optional order to form a first mixture; and

admixing said first mixture with said water-soluble aluminum compound.

In yet another aspect of the present invention, there is provided the use of a composition including:

- (a) a water-soluble aluminum compound being in a concentration of from 0.01 mol/litre to 0.5 mole/litre of said composition and being contained in an amount of from 1% w/v to 10% w/v of said composition;
 - (b) tannic acid in an amount of from 0.01% w/v to 2.0% w/v;
 - (c) an antioxidant in an amount of 50% w/w to 200% w/w with respect to said tannic acid; and
 - (d) a chelating agent in an amount of from 10% w/w to 80% w/w with respect of said water-soluble aluminum compound;
- said composition having a pH range of from pH1.0 to pH3.5;

in the preparation of an injectable medicament for treating hemorrhoidal tissues in a patient by applying an effective amount of said injectable medicament to hemorrhoidal tissue of said patient in the form of an injection.

This is the replacement sheet

Date: 11 FEB 1999

25 The composition according to the present invention may further comprise the polyvalent alcohol and/or saccharide in addition to the formulation consisting of the water-soluble aluminum compound, the chelating agent, tannic acid and sodium hydrogen sulfite, the composition being adjusted, as needed, to a pH ranging from pH1.0 to pH3.5.

30 The water-soluble aluminum compound to be employed for the composition in accordance with the present invention, may be, for example, aluminum chloride, aluminum sulfate, aluminum carbonate, aluminum acetate, aluminum nitrate, aluminum lactate, aluminum tartrate, aluminum salicylate, aluminum sodium sulfate, aluminum potassium sulfate, aluminum cesium sulfate, ammonium aluminum sulfate and the like. The
35 water-soluble aluminum compounds may be applied singly or in combination of two or more.

The water-soluble aluminum compound may be formulated in concentrations ranging usually from 0.01 to 0.5 mole/litre, preferably from 0.03 to 0.3 mole./litre. It is preferred that the water-soluble aluminum compound is contained so as to amount to from approximately 1% w/w to
5 10% w/w, preferably from approximately 2% w/w to 5% w/w of the composition.

As tannic acid to be employed in the composition according to the present invention, there may be employed one derived from a variety of plants. The most preferred one is tannic acid derived from gallnut. Tannic
10 acid may be contained in an amount ranging usually from 0.01% w/w to 2.0% w/w, preferably from 0.05% w/w to 1.5% w/w of the composition. The tannic acid may be added in a concentration beyond the above range by adjusting the amounts of the other components, particularly sodium hydrogen sulfite; however, in this case, care should be paid in preparing and storing the
15 compositions because the resulting compositions are likely to cause coloring or precipitating or depositing during storage for a long period of time. In this sense, such compositions are inconvenient in handling.

As described hereinabove, aluminum potassium sulfate may be decomposed to form aluminum ions such as Al^{3+} , $\text{Al}(\text{OH})^{2+}$, $\text{Al}(\text{OH})^+$ and the
20 like upon dissociation in the solution and react with hydroxyl ion, OH^- , to form aluminum hydroxide, $\text{Al}(\text{OH})_3$. If such aluminum ions are present in the solution, tannic acid is reacted directly with them, whereby the solution is likely to cause precipitating.

This is the replacement sheet

Date: 11 FEB 1999

As the chelating agent to be employed for the present invention, there
25 may be mentioned any compound having the action of trapping minute
amounts of metal ions present in the solution. The chelating agent may
include, for example, citric acid or a salt thereof such as sodium citrate. The
amount of the chelating agent may be in the range of from approximately
10% w/w to 80% w/w, preferably from approximately 20% w/w to 50% w/w
30 with respect to the amount of the water-soluble aluminum compound,
although the amount of the chelating agent may be varied with the kind or
the amount of the water-soluble aluminum compound, or the like.

In preparing the compositions for treating hemorrhoidal tissues in
accordance with the present invention, the chelating agent such as sodium
35 citrate is added to a solution containing the water-soluble aluminum
compound before formulating tannic acid with the water-soluble aluminum
compound, in order to avoid the direct reaction of the tannic acid with the
water-soluble aluminum compound and to avoid precipitation. Once the
chelating agent is added to the solution containing the water-soluble
5 aluminum compound, the chelating agent is caused to react with the
aluminum ions present in the solution, resulting in the formation of complex
aluminum ions and removal of metal ions from the solution to which tannic
acid is to be added, the metal ions being reactable with the tannic acid and as
a result being likely to cause precipitation. To the solution treated in the
10 manner as described hereinabove is added tannic acid to thereby yield a
solution in which the tannic acid does not react directly with the metal ions,
such as aluminum ions, derived from the water-soluble aluminum compound
and in which no precipitates are formed. Theoretically, for example, if 0.65
molecule of the aluminum ion is present with respect to one molecule of
15 sodium citrate ion and the former is to be linked to the latter, no free
aluminum ion is present in the solution. Practically, however, as the sodium
citrate ion exists in a neutral state or in the form of a citric acid dihydrogen
ion in the range of such a strong acid as the composition according to the
present invention, such amounts are insufficient to trap the aluminum ions
20 in the 1.65-fold concentrations as complex ions. Hence, in this case, it is
preferred to select a solution having the composition so as to allow free
aluminum ions to exist in a range that does not exceed a solubility product
constant of aluminum tannate.

Further, tannic acid is unstable in light or air in a solid state and it is
25 lesser stable in solution from the point of view of a diffusion velocity
between the reactive substances. For the purpose to prevent oxidation of

This is the replacement sheet

Date: 1 1 FEB 1999

tannic acid, there may be used an antioxidant such as, for example, sodium hydrogen sulfite. The amount of sodium hydrogen sulfite to be used as the antioxidant in accordance with the present invention may be usually from approximately 50% w/w to 200% w/w, preferably from approximately 70% w/w to 150% w/w, with respect to the amount of the tannic acid. If the sodium hydrogen sulfite would be contained in a concentration beyond the above range, the resulting injectable preparations cannot accomplish the desired effects sought to be achieved by the present invention.

In order to make the composition according to the present invention more stable, there may be added as needed the polyvalent alcohol and/or saccharide, which are or is conventionally employed for the compositions. As the polyvalent alcohol and/or the saccharide to be employed for the present invention, there may be mentioned glycerin, glucose, fructose, xylitol, mannose, mannitol, galactose, dextran and the like. Particularly, dextran has the action of raising the viscosity of the resulting injectable preparations. The polyvalent alcohol and/or saccharide may be employed singly or in combination of two or more. Further, the amount of the polyvalent alcohol and/or saccharide is not limited to a particular one as long as the polyvalent alcohol and/or saccharide may be contained in an amount so as to raise the osmosis of the resulting injectable preparations by approximately three times to fifteen times, preferably from approximately four times to eight times, that of physiological saline. In addition, the polyvalent alcohol and/or saccharide are or is preferably contained in the range of from approximately 3% w/w to 20% w/w, preferably from approximately 5% w/w to 15% w/w, as the effective concentration in the injectable preparations.

Further, the compositions according to the present invention may contain another component which hitherto has been conventionally employed as an ingredient for compositions, such as an agent for increasing viscosity of a solution, e.g. dextran or the like, or an antiseptic agent, e.g. phenol, benzyl alcohol, benzalkonium chloride, p-aminobenzoic acid ester or the like. These components may optionally be employed within the range that does not substantially affect the effects of the compositions adversely.

In accordance with the present invention, it is of significance in terms of storage of the resulting preparations that the liquid property of the injectable preparations containing the composition is adjusted to be from pH1.0 to pH3.5, preferably from pH2.0 to pH3.0.

When the compositions according to the present

This is the replacement sheet

Date: 11 FEB 1999

The compositions according to the present invention can demonstrate the strong action of killing the cells of the hemorrhoidal tissues while holding the states or shapes of the cells. In other words, it is anticipated that the compositions can kill the cells of the hemorrhoidal tissues upon contact by application and then cause the killed cells to fall off from the normal tissues. By allowing the killed cells to fall off from the normal tissues, the compositions according to the present invention can sclerose the hemorrhoidal tissues and cure them in mild conditions.

BEST MODE FOR CARRYING OUT THE INVENTION

The compositions for curing the affected abnormal tissues (i.e. hemorrhoidal tissues) according to the present invention will be described in more details by way of examples.

Example No. 1:

The composition for curing the affected abnormal tissues according to this example contained the following components:

Aluminum potassium sulfate	400mg
Sodium citrate	150mg
Sodium hydrogen sulfite	15mg
Tannic acid	15mg
Dextran 50	70mg
Glycerin	1,000mg
Injectable distilled water	To make 10ml

The injectable distilled water prepared so as to comply with Pharmacopedia Japonica was treated to remove dissolved oxygen by heating it at 100°C for five minutes. After the completion of heating, nitrogen gases were introduced into the treated water and allowed to cool to room temperature.

Separately, the total amount of dextran 40 was fully dissolved in an appropriate solvent in advance because it is less soluble to the solution for use.

CLAIMS.

1. A method for preparing an injectable composition for treating hemorrhoidal tissues said composition including:

- 5 (a) a water-soluble aluminum compound being in a concentration of from 0.01 mol/litre to 0.5 mole/litre of said composition and being contained in an amount of from 1% w/v to 10% w/v of said composition;
- (b) tannic acid in an amount of from 0.01% w/v to 2.0% w/v;
- 10 (c) an antioxidant in an amount of 50% w/w to 200% w/w with respect to said tannic acid; and
- (d) a chelating agent in an amount of from 10% w/w to 80% w/w with respect of said water-soluble aluminum compound;

said composition having a pH range of from pH1.0 to pH3.5;

said method comprising the steps of:

- 15 (e) admixing said water-soluble aluminum compound with said chelating agent to form a first mixture; and
- (f) admixing said first mixture with said tannic acid and said antioxidant or with a mixture of said tannic acid and said antioxidant.

2. A method for preparing an injectable composition for treating hemorrhoidal tissues said composition including:

- (a) a water-soluble aluminum compound being in a concentration of from 0.01 mol/litre to 0.5 mole/litre of said composition and being contained in an amount of from 1% w/v to 10% w/v of said composition;
- 25 (b) tannic acid in an amount of from 0.01% w/v to 2.0% w/v;
- (c) an antioxidant in an amount of 50% w/w to 200% w/w with respect to said tannic acid; and
- (d) a chelating agent in an amount of from 10% w/w to 80% w/w with respect of said water-soluble aluminum compound;
- 30 said composition having a pH range of from pH1.0 to pH3.5;

comprising the steps of:

- (e) admixing said tannic acid with said antioxidant to form a first mixture; and
- 35 (f) admixing said first mixture with said water-soluble aluminum compound and said chelating agent or with a mixture of said water-soluble aluminum compound and said chelating agent.

This is the replacement sheet



Date: 11 FEB 1999

3. A method for preparing an injectable composition for treating hemorrhoidal tissues said composition including:

- (a) a water-soluble aluminum compound being in a concentration of from 0.01 mol/litre to 0.5 mole/litre of said composition and being contained in an amount of from 1% w/v to 10% w/v of said composition;
 - (b) tannic acid in an amount of from 0.01% w/v to 2.0% w/v;
 - (c) an antioxidant in an amount of 50% w/w to 200% w/w with respect to said tannic acid; and
 - (d) a chelating agent in an amount of from 10% w/w to 80% w/w with respect of said water-soluble aluminum compound;
- said composition having a pH range of from pH1.0 to pH3.5;

comprising the steps of:

- (e) admixing said water-soluble aluminum compound, said chelating agent and said antioxidant in an optional order to form a first mixture; and
- (f) admixing said first mixture with said tannic acid.

4. A method for preparing an injectable composition for treating hemorrhoidal tissues said composition including:

- (a) a water-soluble aluminum compound being in a concentration of from 0.01 mol/litre to 0.5 mole/litre of said composition and being contained in an amount of from 1% w/v to 10% w/v of said composition;
 - (b) tannic acid in an amount of from 0.01% w/v to 2.0% w/v;
 - (c) an antioxidant in an amount of 50% w/w to 200% w/w with respect to said tannic acid; and
 - (d) a chelating agent in an amount of from 10% w/w to 80% w/w with respect of said water-soluble aluminum compound;
- said composition having a pH range of from pH1.0 to pH3.5;

comprising the steps of:

- (e) admixing said tannic acid, said chelating agent and said antioxidant in an optional order to form a first mixture; and
- (f) admixing said first mixture with said water-soluble aluminum compound.

5. The method as claimed in any one of Claims 1 to 4, wherein a polyvalent alcohol and/or a saccharide are or is added in an optional step.



This is the replacement sheet

Date:

11 FEB 1999

6. The method as claimed in any one of Claims 1 to 5, wherein each of components constituting said composition or either of said components is formulated with each other under inert atmosphere.

5 7. The method as claimed in any one of Claims 1 to 5, wherein oxygen exists in atmosphere or in water to be used in no substantial amount or such a restricted amount as failing to adversely affect said composition.

8. The method as claimed in any one of Claims 1 to 7, wherein a pH is adjusted, as needed, so as to allow said composition to become in the range of from pH1.0 to pH3.5.

10 9. The method as claimed in any one of Claims 1 to 8, wherein a pH is adjusted in any optional step, as needed, so as to allow said composition to become in the range of from pH2.0 to pH3.0.

10. The method as claimed in any one of Claims 1 to 9, further comprising the step of filling said composition in a container in inert atmosphere for use
15 upon injection or for storage.

11. The use of a composition including:

(a) a water-soluble aluminum compound being in a concentration of from 0.01 mol/litre to 0.5 mole/litre of said composition and being
20 contained in an amount of from 1% w/v to 10% w/v of said composition;

(b) tannic acid in an amount of from 0.01% w/v to 2.0% w/v;

(c) an antioxidant in an amount of 50% w/w to 200% w/w with respect to said tannic acid; and

25 (d) a chelating agent in an amount of from 10% w/w to 80% w/w with respect of said water-soluble aluminum compound;

said composition having a pH range of from pH1.0 to pH3.5;

in the preparation of an injectable medicament for treating hemorrhoidal tissues in a patient by applying an effective amount of said injectable medicament to hemorrhoidal tissue of said patient in the form of an injection.

30 12. A method according to claim 11, wherein said composition is applied to treat piles or hemorrhoids, uplift affected tissues of the digestive system or hepatic tumor.



This is the replacement sheet

Date: 11 FEB 1999